<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v3.0 20080202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing3.dtd?><?SourceDTD.Version 3.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4393144</article-id><article-id pub-id-type="pmid">25860442</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0123931</article-id><article-id pub-id-type="publisher-id">PONE-D-14-56048</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Bone Marrow Stromal Antigen 2 (BST-2) DNA Is Demethylated in Breast Tumors and Breast Cancer Cells</article-title><alt-title alt-title-type="running-head">Epigenetic Regulation of BST-2 Expression in Breast Cancer</alt-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Mahauad-Fernandez</surname><given-names>Wadie D.</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Borcherding</surname><given-names>Nicholas C.</given-names></name><xref ref-type="aff" rid="aff003"><sup>3</sup></xref><xref ref-type="aff" rid="aff004"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Weizhou</given-names></name><xref ref-type="aff" rid="aff002"><sup>2</sup></xref><xref ref-type="aff" rid="aff003"><sup>3</sup></xref><xref ref-type="aff" rid="aff004"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Okeoma</surname><given-names>Chioma M.</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref><xref rid="cor001" ref-type="corresp">*</xref></contrib></contrib-group><aff id="aff001"><label>1</label><addr-line>Department of Microbiology, Carver College of Medicine, University of Iowa, Iowa City, Iowa, United States of America</addr-line></aff><aff id="aff002"><label>2</label><addr-line>Interdisciplinary Graduate program in Molecular and Cellular Biology (MCB), University of Iowa, Iowa City, Iowa, United States of America</addr-line></aff><aff id="aff003"><label>3</label><addr-line>Department of Pathology, Carver College of Medicine, University of Iowa, Iowa City, Iowa, United States of America</addr-line></aff><aff id="aff004"><label>4</label><addr-line>Medical Scientist Training Program, Carver College of Medicine, University of Iowa, Iowa City, Iowa, United States of America</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Coleman</surname><given-names>William B.</given-names></name><role>Academic Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>University of North Carolina School of Medicine, UNITED STATES</addr-line></aff><author-notes><fn fn-type="conflict" id="coi001"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="con" id="contrib001"><p>Conceived and designed the experiments: CMO. Performed the experiments: WDM NB. Analyzed the data: WDM NB WZ CMO. Contributed reagents/materials/analysis tools: WZ CMO. Wrote the paper: WDM NB WZ CMO.</p></fn><corresp id="cor001">* E-mail: <email>chioma-okeoma@uiowa.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>10</day><month>4</month><year>2015</year></pub-date><pub-date pub-type="collection"><year>2015</year></pub-date><volume>10</volume><issue>4</issue><elocation-id>e0123931</elocation-id><history><date date-type="received"><day>14</day><month>12</month><year>2014</year></date><date date-type="accepted"><day>9</day><month>3</month><year>2015</year></date></history><permissions><copyright-year>2015</copyright-year><copyright-holder>Mahauad-Fernandez et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="pone.0123931.pdf"/><abstract><sec id="sec001"><title>Background</title><p>Bone marrow stromal antigen 2 (BST-2) is a known anti-viral gene that has been recently identified to be overexpressed in many cancers, including breast cancer. BST-2 is critical for the invasiveness of breast cancer cells and the formation of metastasis <italic>in vivo</italic>. Although the regulation of BST-2 in immune cells is unraveling, it is unknown how BST-2 expression is regulated in breast cancer. We hypothesized that meta-analyses of BST-2 gene expression and BST-2 DNA methylation profiles would illuminate mechanisms regulating elevated BST-2 expression in breast tumor tissues and cells.</p></sec><sec id="sec002"><title>Materials and Methods</title><p>We performed comprehensive meta-analyses of BST-2 gene expression and BST-2 DNA methylation in The Cancer Genome Atlas (TCGA) and various Gene Expression Omnibus (GEO) datasets. BST-2 expression levels and BST-2 DNA methylation status at specific CpG sites on the BST-2 gene were compared for various breast tumor molecular subtypes and breast cancer cell lines.</p></sec><sec id="sec003"><title>Results</title><p>We show that BST-2 gene expression is inversely associated with the methylation status at specific CpG sites in primary breast cancer specimens and breast cancer cell lines. BST-2 demethylation is significantly more prevalent in primary tumors and cancer cells than in normal breast tissues or normal mammary epithelial cells. Demethylation of the BST-2 gene significantly correlates with its mRNA expression. These studies provide the initial evidence that significant differences exist in BST-2 DNA methylation patterns between breast tumors and normal breast tissues, and that BST-2 expression patterns in tumors and cancer cells correlate with hypomethylated BST-2 DNA.</p></sec><sec id="sec004"><title>Conclusion</title><p>Our study suggests that the DNA methylation pattern and expression of BST-2 may play a role in disease pathogenesis and could serve as a biomarker for the diagnosis of breast cancer.</p></sec></abstract><funding-group><funding-statement>This work was supported by funds from the National Institutes of Health under Award Numbers T32 GM007337 (NB) and P30CA086862. Our work also benefited from Grant IRG-77-004-34 from the American Cancer Society, administered through The Holden Comprehensive Cancer Center at The University of Iowa. The results here are in whole or part based upon data generated by the TCGA Research Network (<ext-link ext-link-type="uri" xlink:href="http://cancergenome.nih.gov/">http://cancergenome.nih.gov/</ext-link>).</funding-statement></funding-group><counts><fig-count count="6"/><table-count count="1"/><page-count count="17"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All of our data are within the paper.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All of our data are within the paper.</p></notes></front><body><sec sec-type="intro" id="sec005"><title>Introduction</title><p>Breast cancer is the second largest cause of cancer-related deaths in women according to the National Cancer Institute (NCI) and is the second most common cancer diagnosed in women. Treatment for breast cancer is dependent on its subtype classification [<xref rid="pone.0123931.ref001" ref-type="bibr">1</xref>]. The most severe forms of breast cancer which respond poorly to hormonal or targeted therapies include luminal B and basal breast cancers [<xref rid="pone.0123931.ref002" ref-type="bibr">2</xref>,<xref rid="pone.0123931.ref003" ref-type="bibr">3</xref>]. The inability to develop new treatments is partially due to a limited understanding of all the drivers of these malignancies which give transformed cells a selective advantage over normal cells to grow and thrive in unfavorable environments.</p><p>One of the drivers of breast malignancy is BST-2 [<xref rid="pone.0123931.ref004" ref-type="bibr">4</xref>], also known as Tetherin, CD317, or HM1.24. BST-2 is an IFN-inducible type II transmembrane protein expressed mainly at the surface of cells [<xref rid="pone.0123931.ref005" ref-type="bibr">5</xref>,<xref rid="pone.0123931.ref006" ref-type="bibr">6</xref>]. BST-2 contains an N-terminus cytoplasmic tail followed by a transmembrane domain, an extracellular coiled-coiled domain and a C-terminus glycophosphatidylinositol (GPI) anchor embedded in lipid rafts along the cell membrane [<xref rid="pone.0123931.ref005" ref-type="bibr">5</xref>,<xref rid="pone.0123931.ref007" ref-type="bibr">7</xref>]. BST-2 was discovered as a marker of differentiated B cells [<xref rid="pone.0123931.ref008" ref-type="bibr">8</xref>] and was later rediscovered as a potent antiviral restriction factor with the ability to tether enveloped viruses to the cell membrane of infected cells via its GPI anchor [<xref rid="pone.0123931.ref009" ref-type="bibr">9</xref>&#x02013;<xref rid="pone.0123931.ref012" ref-type="bibr">12</xref>], as well as to potently inhibit virus replication in cultured cells and <italic>in vivo</italic> [<xref rid="pone.0123931.ref011" ref-type="bibr">11</xref>,<xref rid="pone.0123931.ref013" ref-type="bibr">13</xref>,<xref rid="pone.0123931.ref014" ref-type="bibr">14</xref>]. BST-2 is thought to mediate host immune response by activating NF-&#x0043a;B through interaction with transforming growth factor beta-activated kinase 1(TAK1) and TNF receptor associated factors (TRAFs) 2 and 6 [<xref rid="pone.0123931.ref014" ref-type="bibr">14</xref>&#x02013;<xref rid="pone.0123931.ref016" ref-type="bibr">16</xref>]. In addition, BST-2 induces antibody-dependent cell cytotoxicity (ADCC) against the envelope protein of HIV [<xref rid="pone.0123931.ref017" ref-type="bibr">17</xref>&#x02013;<xref rid="pone.0123931.ref019" ref-type="bibr">19</xref>].</p><p>Recent studies have demonstrated that the mRNA and protein expression of BST-2 are elevated in various cancers including: head and neck cancer, oral cavity cancer, glioblastoma, lung cancer, endometrial cancer, lymphomas, and breast cancers [<xref rid="pone.0123931.ref020" ref-type="bibr">20</xref>&#x02013;<xref rid="pone.0123931.ref026" ref-type="bibr">26</xref>]. There is direct evidence for a role for BST-2 in two cancers. BST-2 antibody-mediated ADCC has been shown to be potent in myeloma treatment [<xref rid="pone.0123931.ref027" ref-type="bibr">27</xref>,<xref rid="pone.0123931.ref028" ref-type="bibr">28</xref>] and in breast cancer, BST-2 plays a direct role in driving breast malignancy [<xref rid="pone.0123931.ref004" ref-type="bibr">4</xref>]. In vivo, elevated BST-2 expression is associated with primary tumor growth, metastasis, and poor prognosis [<xref rid="pone.0123931.ref004" ref-type="bibr">4</xref>]. Upon BST-2 knockdown, breast cancer cells lose their capacity to grow and thrive <italic>in vivo</italic> [<xref rid="pone.0123931.ref004" ref-type="bibr">4</xref>]. The molecular mechanisms involved in BST-2-mediated breast cancer malignancy includes; BST-2-meditated enhancement in cancer cell i) adhesion to the tumor microenvironment, ii) migration through the basement membrane, iii) invasion through extracellular matrix lattice, and anchorage independent growth [<xref rid="pone.0123931.ref004" ref-type="bibr">4</xref>,<xref rid="pone.0123931.ref029" ref-type="bibr">29</xref>]. In contrast to breast cancer, knock down of BST-2 in glioblastoma had no effect on tumor growth in mice [<xref rid="pone.0123931.ref022" ref-type="bibr">22</xref>].</p><p>Despite the functions of BST-2 in breast oncogenesis, little is known about the regulation of BST-2 expression in cancer cells. Sayeed <italic>et al</italic>., (2013) reported that BST-2 expression in tumor tissues and primary breast cancer cell lines is negatively regulated by transforming growth factor beta (TGF-&#x003b2;) [<xref rid="pone.0123931.ref030" ref-type="bibr">30</xref>]. However, there is no evidence for genetic or epigenetic modifications that regulate BST-2 expression in breast cancer tissue/cells.</p><p>The process of carcinogenesis is characterized by genetic and epigenetic modifications. Epigenetic alterations and regulation of gene functions is increasingly being recognized as critical in carcinogenesis [<xref rid="pone.0123931.ref031" ref-type="bibr">31</xref>]. These alterations may involve histone modifications and changes in DNA methylation status of cytosine bases (C) in the context of CpG dinucleotides.</p><p>The result of alterations in DNA methylation status is changes in gene expression patterns that may perturb normal cell physiology and function. There is an inverse correlation between gene expression and DNA methylation status [<xref rid="pone.0123931.ref032" ref-type="bibr">32</xref>,<xref rid="pone.0123931.ref033" ref-type="bibr">33</xref>]. As such, hypermethylation of DNA silences gene expression [<xref rid="pone.0123931.ref032" ref-type="bibr">32</xref>] whereas hypomethylation or demethylation of DNA enables gene expression [<xref rid="pone.0123931.ref034" ref-type="bibr">34</xref>]. Both hypermethylation and hypomethylation play important but distinct roles in the initiation, progression, and metastasis of various cancers [<xref rid="pone.0123931.ref035" ref-type="bibr">35</xref>,<xref rid="pone.0123931.ref036" ref-type="bibr">36</xref>]. Here, we aimed to determine the source of BST-2 overexpression in breast tumors through <italic>in silico</italic> and <italic>in vitro</italic> analyses. We report that BST-2 expression in breast tumors and cancer cells is epigenetically regulated by hypomethylation or demethylation of specific CpG sites along the BST-2 gene.</p></sec><sec sec-type="materials|methods" id="sec006"><title>Methods</title><sec id="sec007"><title>Cell lines</title><p>Normal human mammary epithelial cell line HMLE, luminal A breast cancer cell lines MCF-7 and T47D, luminal B cell line BT-474, HER2+ cell line SK-BR-3, triple negative MDA-MB-231 cell line, and basal breast cancer cell line SUM-159 are from ATCC and were maintained according to ATCC instructions.</p></sec><sec id="sec008"><title>Gene expression and methylation analysis</title><p>The UCSC Cancer Genome Browser (<ext-link ext-link-type="uri" xlink:href="https://genome-cancer.ucsc.edu/">https://genome-cancer.ucsc.edu</ext-link>) [<xref rid="pone.0123931.ref037" ref-type="bibr">37</xref>] was used to assess BST-2 expression for the PAN-CAN-normalized samples [<xref rid="pone.0123931.ref038" ref-type="bibr">38</xref>,<xref rid="pone.0123931.ref039" ref-type="bibr">39</xref>] for the indicated cancer types and their corresponding normal tissues. Separately, expression and methylation values from the individual BRCA cohort of the TCGA were used. Expression versus methylation analyses were performed with mean-centralized level 3 Illumina HiSeq 2000 RNAseq expression data and Infinium HumanMethylation450 beta-values. Methylation beta-values are reported as either an average of all probes or by the specific probe for BST-2. Probes on the BST-2 gene (Chromosome 19) used in these analyses are: probe 1 cg22282590 (position: 17514117), probe 2 cg07839313 (position: 17514600), probe 3 cg12090003 (position: 17516282), probe 4 cg16363586 (position: 17516329), probe 5 cg11558551 (position: 17516442), probe 6 cg01254505 (position: 17516470), probe 7 cg01329005 (position: 17516712), probe 8 cg09993699 (position: 17517008) and probe 9 cg20092122 (position: 17517221). Probe sequences can be downloaded at Illumina Infinium HumanMethylation450K Bead Chip product page at <ext-link ext-link-type="uri" xlink:href="http://support.illumina.com/array/array_kits/infinium_humanmethylation450_beadchip_kit/downloads.html">http://support.illumina.com/array/array_kits/infinium_humanmethylation450_beadchip_kit/downloads.html</ext-link>. Samples were divided into indicated categorical groups using the Biotab clinical information available at the TCGA DCC (<ext-link ext-link-type="uri" xlink:href="https://tcga-data.nci.nih.gov/tcga/">https://tcga-data.nci.nih.gov/tcga/</ext-link>). Differences in sample number in figures are a result of sorting by categorical data, i.e. primary tumor samples that have PAM50 subtypes are less than the total number of primary samples with RNAseq expression. Expression values were also sorted by sample type, PAM50 subtype from RNAseq (TCGA AWG), and pathological stage. Analysis of BST-2 expression from different breast cancer subtypes was performed only with normal and primary tumor samples. Data from metastatic tumors were excluded from those analyses (&#x0003c;10 metastatic samples), but were used for the analysis of BST-2 expression between normal mammary tissue (Normal), primary tumors (Tumor), and metastatic tumors (Metastatic) (<xref rid="pone.0123931.g001" ref-type="fig">Fig 1D</xref>). All TCGA data was processed and analyzed using Graph Prism software. In addition, five datasets from the Gene Expression Omnibus (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/geo/">http://www.ncbi.nlm.nih.gov/geo/</ext-link>) were used: 1) GEO dataset GSE10797 [<xref rid="pone.0123931.ref040" ref-type="bibr">40</xref>] was used to analyze BST-2 and APOBEC3G (A3G) expression in the epithelium and stroma from normal and cancer tissues of patients undergoing surgical resection or reduction mammoplasty, 2) expression of BST-2 in different human breast cancer cell lines was analyzed using the dataset GSE41313 (only data for MCF-7, T47D, MDA-MB-231, and SUM-159 cells were downloaded) [<xref rid="pone.0123931.ref041" ref-type="bibr">41</xref>], 3) methylation and 4) expression pattern of the BST-2 gene in different human breast cancer cell lines was analyzed with GEO datasets GSE49794 and GSE45732, respectively. These datasets encompass a data superseries derived from the same cells and the same experiment [<xref rid="pone.0123931.ref042" ref-type="bibr">42</xref>], and 5) the effects of 5-aza-2&#x02019;-deoxycytidine (DAC) treatment on BST-2, Claudin-6, and GAPDH expression in several human breast cancer cell lines was evaluated with the dataset GSE28976 (for HMLE, SK-BR-3 and MDA-MB-231 cells only) [<xref rid="pone.0123931.ref043" ref-type="bibr">43</xref>] and GSE36683 [<xref rid="pone.0123931.ref044" ref-type="bibr">44</xref>] (for MCF-7 cells only). Control and DAC treated samples were used. Cell line methylation versus expression analysis was conducted using the same methylation probe IDs listed previously. Methylation probes are reported as either independent beta-values or the average of probes 3&#x02013;9 beta-values where indicated. Expression was derived from RNAseq data of GSE45732 and reported in reads per kilobases per million reads mapped (RPKM). All GEO data sets were processed and analyzed using Graph Prism software.</p><fig id="pone.0123931.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0123931.g001</object-id><label>Fig 1</label><caption><title>Various cancer types including breast cancer have different levels of BST-2 expression.</title><p>(A) to (C) BST-2 transcript levels in paired normal (N) and tumor (T) tissues of patients bearing different cancer types. Data analyzed are from TCGA. Lung adenocarcinoma = Lung A. C., Lung Squamous Cell Carcinoma = Lung S. C. C., Kidney Papillary Cell Carcinoma = Kidney P. C. C., Kidney Clear Cell Carcinoma = Kidney C. C. C. (D) BST-2 mRNA levels of normal, primary tumor, and metastatic tumor of invasive breast cancer bearing patients from TCGA repository. (E) BST-2 mRNA levels in different breast cancer subtypes. BST-2 levels in all tumor subtypes are compared to the BST-2 level in normal tissues. Data does not include metastatic tumors. (F) to (I) Box plots of BST-2 transcript levels in stages I, II, III, and IV of (F) luminal A, (G) luminal B, (H) HER2-enriched, and (I) basal breast cancers. Data does not include metastatic tumors. (J) BST-2 mRNA levels in different breast cancer cell lines. BST-2 levels in all cancer cell lines are compared to BST-2 levels in normal HMLE cells and normalized to GAPDH. (K) BST-2 surface expression from HMLE, MCF-7, BT-474, SK-BR-3 and MDA-MB-231 cells as determined by flow cytometry. Numbers in parenthesis correspond to BST-2 expression presented as a percentage. Significance was taken at P&#x0003c;0.05 (*), P&#x0003c;0.01 (**) and P&#x0003c;0.001 (****). Error bars correspond to standard error of the mean (SEM) and n.s = not significant.</p></caption><graphic xlink:href="pone.0123931.g001"/></fig></sec><sec id="sec009"><title>5-Azacytidine treatment and Flow Cytometry</title><p>Cell lines of interest were plated at 150,000 cells/well in a 6-well plate and treated with DMSO (vehicle) or 1 &#x003bc;M of 5-azacytidine (5-azaC, Sigma Aldrich) for 5 days. Cells were harvested using 0.25% trypsin-EDTA (Mediatech, Corning, NY, USA). Post-incubation, 8 ml of 10% FBS-containing RPMI media (Life Technologies) was added and cells were centrifuged. Media was aspirated and individual cells were resuspended in 2% FBS-containing PBS (Life Technologies). Cell suspension was passed through a 40 &#x003bc;M cell strainer (Falcon). Cells were incubated at 4&#x000b0;C for 1 hour with APC-conjugated anti-BST-2 primary antibodies or appropriate IgG (Ebioscience) and washed with 1x PBS. After washing, cells were incubated with the fluorescent intercalator&#x02014;7-aminoactinomycin D (7-AAD) (BioLegend) at 4&#x000b0;C for 30 minutes to exclude dead cells. Stained cells were quantified using a FACS Calibur flow cytometer (BD). 10,000 events were collected per sample and FACS data were analyzed and plotted using Flowjo software (TreeStar).</p></sec><sec id="sec010"><title>5-Azacytidine treatment and reverse transcriptase quantitative real time PCR (RT-qPCR)</title><p>Human normal and breast cancer cell lines were plated at 150,000 cells/well in a 6-well plate and treated with DMSO (vehicle) or 1 &#x003bc;M of 5-azacytidine (5-azaC, Sigma Aldrich) for 5 days. Cells were lifted using Versene (a gentle cell dissociator, Life Technologies), washed with PBS, pelleted and stored at -20&#x000b0;C until required for analysis. RNA was isolated from frozen cells using the RNeasy mini kit (Qiagen) according to manufacturer's instructions. Equivalent amounts of RNA were treated with DNase (Qiagen). A portion of RNA was subjected to cDNA synthesis (ABI) as previously described [<xref rid="pone.0123931.ref012" ref-type="bibr">12</xref>,<xref rid="pone.0123931.ref045" ref-type="bibr">45</xref>&#x02013;<xref rid="pone.0123931.ref047" ref-type="bibr">47</xref>]. RNA concentration and purity were assessed at 260/280 nm using the spectrophotometer. Using synthesized cDNA, sequence-specific primers were used to amplify BST-2 [<xref rid="pone.0123931.ref004" ref-type="bibr">4</xref>] and GAPDH [<xref rid="pone.0123931.ref013" ref-type="bibr">13</xref>,<xref rid="pone.0123931.ref048" ref-type="bibr">48</xref>]. Claudin-6 was amplified with (F: GGAGGAGAAGGATTCCAAGG, R: AGCCACCAGGGGGTTATAGA) primer pair. RT-qPCR was carried out with an ABI 7500 FAST thermal cycler in triplicates as previously described [<xref rid="pone.0123931.ref011" ref-type="bibr">11</xref>&#x02013;<xref rid="pone.0123931.ref013" ref-type="bibr">13</xref>,<xref rid="pone.0123931.ref045" ref-type="bibr">45</xref>,<xref rid="pone.0123931.ref046" ref-type="bibr">46</xref>,<xref rid="pone.0123931.ref048" ref-type="bibr">48</xref>&#x02013;<xref rid="pone.0123931.ref050" ref-type="bibr">50</xref>].</p></sec><sec id="sec011"><title>Statistical analysis</title><p>Statistical analysis of significant differences was performed with Unpaired t test with Welch's correction (GraphPad Prism software). Error bars represent standard error of the mean (SEM) or 95% confidence interval (CI) of the mean. Correlation studies were carried out using GraphPad Prism software to calculate r<sup>2</sup> and p values. r<sup>2</sup> values of -0.30 or lower (inverse correlations) were considered significant. A p value of 0.05 or lower was considered significant.</p></sec></sec><sec sec-type="results" id="sec012"><title>Results</title><sec id="sec013"><title>BST-2 is differentially expressed in various cancers</title><p>To understand the spectrum of BST-2 expression in various cancers, we analyzed the expression pattern of BST-2 mRNA in various tumors across the TCGA. Results reveal that levels of BST-2 expression in various cancer types differ. Compared to normal tissues, BST-2 expression in tumors is either unchanged (<xref rid="pone.0123931.g001" ref-type="fig">Fig 1A</xref>), significantly downregulated (<xref rid="pone.0123931.g001" ref-type="fig">Fig 1B</xref>), or significantly elevated (<xref rid="pone.0123931.g001" ref-type="fig">Fig 1C</xref>). In breast cancer, BST-2 expression is highest in metastatic tumors compared to primary tumors, and normal mammary gland tissues have the lowest expression (<xref rid="pone.0123931.g001" ref-type="fig">Fig 1D</xref>). Evaluation of BST-2 expression in different breast cancer subtypes show that while all cancer subtypes have elevated BST-2, tumors categorized as luminal B subtype has the highest BST-2 level compared to normal mammary tissue (<xref rid="pone.0123931.g001" ref-type="fig">Fig 1E</xref>). Although BST-2 expression in HER2 and basal tumor subtypes is not statistically different from normal tissues, it is well stablished that BST-2 is overexpressed in the most aggressive forms of breast cancer [<xref rid="pone.0123931.ref004" ref-type="bibr">4</xref>,<xref rid="pone.0123931.ref030" ref-type="bibr">30</xref>]. The lack of significance could be due to the high variability within the basal group (<xref rid="pone.0123931.g001" ref-type="fig">Fig 1E</xref>) and fewer data points for HER2 subtype. In addition, data points used in our analysis came from primary tumors only because metastatic samples within each subtype were excluded since there were insufficient data points for metastatic tumors.</p><p>Comparison of BST-2 expression levels in the different stages within the different subtypes show significant disease stage-dependent differences in BST-2 mRNA in the luminal tumor types compared to normal breast tissue (Fig <xref rid="pone.0123931.g001" ref-type="fig">1F</xref> and <xref rid="pone.0123931.g001" ref-type="fig">1I</xref>). However, BST-2 expression in the different disease stages of HER2 (<xref rid="pone.0123931.g001" ref-type="fig">Fig 1H</xref>) and basal (<xref rid="pone.0123931.g001" ref-type="fig">Fig 1I</xref>) tumor types was not different from normal tissues except for a modest significant difference (<italic>p&#x0003c; 0</italic>.<italic>0313</italic>) in stage II of basal tumors (<xref rid="pone.0123931.g001" ref-type="fig">Fig 1I</xref>). Host dependent variability in BST-2 levels and/or the small number of data points may have affected statistical analysis. Data presented in Fig <xref rid="pone.0123931.g001" ref-type="fig">1E</xref> to <xref rid="pone.0123931.g001" ref-type="fig">1I</xref> do not include metastatic tumors because there were few data points available.</p><p>To evaluate the level of BST-2 expression in different metastatic cells, we utilized breast cancer cell lines that originated from various metastatic sites. BST-2 expression both at the RNA (<xref rid="pone.0123931.g001" ref-type="fig">Fig 1J</xref>) and protein (<xref rid="pone.0123931.g001" ref-type="fig">Fig 1K</xref>) in different metastatic cells directly correlates to their aggressiveness. As such, triple-negative MDA-MB-231 cells presented the highest BST-2 levels followed by HER2 metastatic SK-BR-3 cells, while the luminal cell lines (MCF-7 and BT-474) express lower BST-2 levels (Fig <xref rid="pone.0123931.g001" ref-type="fig">1J</xref> and <xref rid="pone.0123931.g001" ref-type="fig">1K</xref>). These data support the premise that BST-2 levels are elevated in primary and metastatic breast tumor tissues and cell lines.</p></sec><sec id="sec014"><title><italic>BST-2</italic> is hypomethylated in breast tumors</title><p>To probe into the regulatory mechanism of BST-2 overexpression in breast tumors, we analyzed BST-2 methylation beta-values from paired tumor and normal breast tissues. The methylation beta-value was plotted against the corresponding RNA expression. Results reveal that BST-2 mRNA expression is inversely correlated to its DNA methylation status (<xref rid="pone.0123931.g002" ref-type="fig">Fig 2A</xref>) with a highly significant r<sup>2</sup> value of -0.720. The inverse correlation of BST-2 mRNA with BST-2 DNA methylation beta-value signifies that in tumors, <italic>BST-2</italic> is hypo- or demethylated. This prompted us to query the differences in <italic>BST-2</italic> methylation across the entire gene. Comparing paired tumor and normal mammary tissues from the TCGA repository, we found that 7 CpG sites represented by probes 3 to 9 (see <xref rid="sec006" ref-type="sec">methods</xref> section for probe IDs) were significantly hypomethylated in tumors compared to normal tissues (<xref rid="pone.0123931.g002" ref-type="fig">Fig 2B</xref>). In contrast to probes 3 to 9, methylation beta-values for probes 1 and 2 show that these CpG sites are hypermethylated in breast tumors. Overall, these data show that BST-2 DNA is hypomethylated in mammary tumors compared to normal mammary tissue.</p><fig id="pone.0123931.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0123931.g002</object-id><label>Fig 2</label><caption><title>BST-2 DNA in breast tumors is hypomethylated compared to normal tissues.</title><p>(A) BST-2 expression versus methylation plot among all primary tumor (red) and normal (black) breast tissues from BRCA in the TCGA. Beta-value ranges from 0 to 1. Beta-values closer to one depict hypermethylation and closer to 0 depict hypomethylation. (B) Methylation status among different CpG sites in primary tumor (red) and normal (black) breast tissues from invasive breast cancer bearing patients (TCGA). Significance was taken at P&#x0003c;0.05 (*) and P&#x0003c;0.001 (****). Error bars correspond to SEM.</p></caption><graphic xlink:href="pone.0123931.g002"/></fig></sec><sec id="sec015"><title>Hypomethylation of specific CpG sites correlate with BST-2 expression in tumors</title><p>To better understand the effect of <italic>BST-2</italic> methylation on BST-2 expression, we sought to identify CpG sites in the BST-2 gene (<xref rid="pone.0123931.g003" ref-type="fig">Fig 3A</xref>), wherein methylation status was associated with elevated BST-2 expression in tumors compared to normal breast tissues. <xref rid="pone.0123931.g003" ref-type="fig">Fig 3A</xref> portrays the location of the different probes used in the Human Methylation 450 array across the BST-2 gene as described in the methods section. CpG sites corresponding to probes 3 to 7 which are proximal to the BST-2 gene transcription start site (TSS) had the lowest R-squared (r<sup>2</sup>, ranging from -0.4257 to -0.5325) values when plotted against corresponding BST-2 expression in primary tumors (<xref rid="pone.0123931.g003" ref-type="fig">Fig 3B</xref>). In addition, CpG sites downstream (probes 8 and 9) of the TSS did show a significant inverse correlation with tumor tissue BST-2 mRNA expression based on r<sup>2</sup> values of -0.3599 to -0.3606 (<xref rid="pone.0123931.g003" ref-type="fig">Fig 3B</xref>). Moreover, CpG sites upstream (probes 1 and 2) of the TSS are hypermethylated (Fig <xref rid="pone.0123931.g002" ref-type="fig">2A</xref> and <xref rid="pone.0123931.g002" ref-type="fig">2B</xref>) and did not show a strong correlation with tumor tissue BST-2 mRNA expression based on r<sup>2</sup> values of -0.0978 to 0.012 (<xref rid="pone.0123931.g003" ref-type="fig">Fig 3B</xref>). In parallel, correlation between BST-2 methylation beta-values and BST-2 mRNA in normal breast tissues was performed. There was no inverse correlation between CpG methylation and BST-2 expression with any of the 9 probes; r<sup>2</sup> values range from -0.1912 to 0.03254 (<xref rid="pone.0123931.g003" ref-type="fig">Fig 3C</xref>). These data suggest that the CpG sites proximal to BST-2 gene TSS and downstream of the TSS may be responsible for transcriptional regulation of BST-2 in breast tumors.</p><fig id="pone.0123931.g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0123931.g003</object-id><label>Fig 3</label><caption><title>Methylation drives BST-2 expression in breast tumors, but not in normal breast tissue.</title><p>(A) Location of the nine probes included in the Human Methylation 450 array that are associated with the BST-2 gene. Introns are solid gray rectangles while exons are solid black rectangles. (B) and (C) Correlation analysis between BST-2 mRNA levels and methylation values of probes 1 to 9 in (B) primary tumors and (C) normal breast tissues from TCGA. Best-fit line and r<sup>2</sup> values are shown for each probe.</p></caption><graphic xlink:href="pone.0123931.g003"/></fig></sec><sec id="sec016"><title>Hypomethylation of CpG sites proximal to the BST-2 promoter correlate with BST-2 overexpression in different breast tumor subtypes</title><p>Since demethylation of CpG sites strongly associates with increased expression of BST-2 in tumor tissues, we next analyzed the methylation level of BST-2 in different breast cancer subtypes. We found that <italic>BST-2</italic> is hypomethylated on the CpG sites represented by probes 3 to 9 irrespective of tumor subtype (<xref rid="pone.0123931.g004" ref-type="fig">Fig 4A</xref>). To an extent, BST-2 expression could be predicted by the degree of methylation of these probes (<xref rid="pone.0123931.g004" ref-type="fig">Fig 4A</xref>). As such, CpG sites represented by probes 1 and 2 do not mirror BST-2 expression in tumors and were hypermethylated (Fig <xref rid="pone.0123931.g004" ref-type="fig">4A</xref> to <xref rid="pone.0123931.g004" ref-type="fig">4C</xref>). For example, in luminal A tumors, CpG sites represented by probes 1 and 2 are hypermethylated compared to normal breast tissues. Luminal B tumors have the highest level of BST-2 mRNA (<xref rid="pone.0123931.g001" ref-type="fig">Fig 1C</xref>), and presents the lowest methylation values among probes 3, 4, 5, 6, and 7 (Fig <xref rid="pone.0123931.g004" ref-type="fig">4A</xref> to <xref rid="pone.0123931.g004" ref-type="fig">4H</xref>). Compared to normal breast tissues, the luminal tumor types (A and B) are differentially methylated across all probes compared to normal tissues (Fig <xref rid="pone.0123931.g004" ref-type="fig">4B</xref> to <xref rid="pone.0123931.g004" ref-type="fig">4J</xref>). Probes 3 to 9 are hypomethylated in luminal tumors compared to normal tissues while probes 1 and 2 in these tumors are hypermethylated compared to normal tissues, except for probe 1 in luminal B tumors that has a non-significant methylation beta-value compared to normal tissues (<xref rid="pone.0123931.g004" ref-type="fig">Fig 4B</xref>). The HER2 tumor type is hypomethylated at CpG sites represented by probes 3 and 4 (Fig <xref rid="pone.0123931.g004" ref-type="fig">4D</xref> and <xref rid="pone.0123931.g004" ref-type="fig">4E</xref>); while the basal tumor subtype is hypomethylated at CpG sites corresponding to probes 3, 4, 7, 8, and 9 (Fig <xref rid="pone.0123931.g004" ref-type="fig">4D</xref>, <xref rid="pone.0123931.g004" ref-type="fig">4E</xref>, <xref rid="pone.0123931.g004" ref-type="fig">4H</xref> to <xref rid="pone.0123931.g004" ref-type="fig">4J</xref>). These data suggest that <italic>BST-2</italic> methylation pattern at different CpG sites could predict breast cancer subtype (<xref rid="pone.0123931.t001" ref-type="table">Table 1</xref>).</p><fig id="pone.0123931.g004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0123931.g004</object-id><label>Fig 4</label><caption><title>BST-2 DNA methylation pattern in different breast tumor subtypes.</title><p>(A) Methylation status among different CpG sites from different breast cancer subtypes and normal breast tissue. Data does not include metastatic tumors. (B) to (J) Box plots of methylation values among different breast cancer subtypes and normal tissues corresponding to (B) probe 1, (C) probe 2, (D) probe 3, (E) probe 4, (F) probe 5, (G) probe 6, (H) probe 7, (I) probe 8, (J) probe 9. For statistical analysis, each subtype was compared to the normal breast tissue. The luminal subtypes were compared to each other. Significance was taken at P&#x0003c;0.05 (*), P&#x0003c;0.003 (**), P&#x0003c;0.0005 (***), and P&#x0003c;0.0001 (****). Error bars correspond to 95% CI.</p></caption><graphic xlink:href="pone.0123931.g004"/></fig><table-wrap id="pone.0123931.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0123931.t001</object-id><label>Table 1</label><caption><title>Profile of BST-2 DNA hypomethylation in breast cancer subtypes as ranked by significant difference compared to normal breast tissue.</title></caption><alternatives><graphic id="pone.0123931.t001g" xlink:href="pone.0123931.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Probe ID</th><th align="left" rowspan="1" colspan="1">Probe name/ CpG site</th><th align="left" rowspan="1" colspan="1">Luminal A</th><th align="left" rowspan="1" colspan="1">Luminal B</th><th align="left" rowspan="1" colspan="1">HER2</th><th align="left" rowspan="1" colspan="1">Basal-like</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>cg22282590</bold></td><td align="left" rowspan="1" colspan="1"><bold>Probe 1</bold></td><td align="left" rowspan="1" colspan="1"><bold>Hyper (</bold><xref rid="t001fn005" ref-type="table-fn">****</xref><bold>)</bold></td><td align="left" rowspan="1" colspan="1"><bold>unchanged</bold></td><td align="left" rowspan="1" colspan="1"><bold>unchanged</bold></td><td align="left" rowspan="1" colspan="1"><bold>unchanged</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>cg07839313</bold></td><td align="left" rowspan="1" colspan="1"><bold>Probe 2</bold></td><td align="left" rowspan="1" colspan="1"><bold>Hyper (</bold><xref rid="t001fn005" ref-type="table-fn">****</xref><bold>)</bold></td><td align="left" rowspan="1" colspan="1"><bold>Hyper (</bold><xref rid="t001fn005" ref-type="table-fn">****</xref><bold>)</bold></td><td align="left" rowspan="1" colspan="1"><bold>unchanged</bold></td><td align="left" rowspan="1" colspan="1"><bold>unchanged</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>cg12090003</bold></td><td align="left" rowspan="1" colspan="1"><bold>Probe 3</bold></td><td align="left" rowspan="1" colspan="1"><bold>Hypo (</bold><xref rid="t001fn005" ref-type="table-fn">****</xref><bold>)</bold></td><td align="left" rowspan="1" colspan="1"><bold>Hypo (</bold><xref rid="t001fn005" ref-type="table-fn">****</xref><bold>)</bold></td><td align="left" rowspan="1" colspan="1"><bold>Hypo (</bold><xref rid="t001fn004" ref-type="table-fn">***</xref><bold>)</bold></td><td align="left" rowspan="1" colspan="1"><bold>Hypo (</bold><xref rid="t001fn003" ref-type="table-fn">**</xref><bold>)</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>cg16363586</bold></td><td align="left" rowspan="1" colspan="1"><bold>Probe 4</bold></td><td align="left" rowspan="1" colspan="1"><bold>Hypo (</bold><xref rid="t001fn005" ref-type="table-fn">****</xref><bold>)</bold></td><td align="left" rowspan="1" colspan="1"><bold>Hypo (</bold><xref rid="t001fn005" ref-type="table-fn">****</xref><bold>)</bold></td><td align="left" rowspan="1" colspan="1"><bold>Hypo (</bold><xref rid="t001fn002" ref-type="table-fn">*</xref><bold>)</bold></td><td align="left" rowspan="1" colspan="1"><bold>Hypo (</bold><xref rid="t001fn005" ref-type="table-fn">****</xref><bold>)</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>cg11558551</bold></td><td align="left" rowspan="1" colspan="1"><bold>Probe 5</bold></td><td align="left" rowspan="1" colspan="1"><bold>Hypo (</bold><xref rid="t001fn005" ref-type="table-fn">****</xref><bold>)</bold></td><td align="left" rowspan="1" colspan="1"><bold>Hypo (</bold><xref rid="t001fn005" ref-type="table-fn">****</xref><bold>)</bold></td><td align="left" rowspan="1" colspan="1"><bold>unchanged</bold></td><td align="left" rowspan="1" colspan="1"><bold>unchanged</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>cg01254505</bold></td><td align="left" rowspan="1" colspan="1"><bold>Probe 6</bold></td><td align="left" rowspan="1" colspan="1"><bold>Hypo (</bold><xref rid="t001fn005" ref-type="table-fn">****</xref><bold>)</bold></td><td align="left" rowspan="1" colspan="1"><bold>Hypo</bold> (<xref rid="t001fn005" ref-type="table-fn">****</xref><bold>)</bold></td><td align="left" rowspan="1" colspan="1"><bold>unchanged</bold></td><td align="left" rowspan="1" colspan="1"><bold>unchanged</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>cg01329005</bold></td><td align="left" rowspan="1" colspan="1"><bold>Probe 7</bold></td><td align="left" rowspan="1" colspan="1"><bold>Hypo (</bold><xref rid="t001fn005" ref-type="table-fn">****</xref><bold>)</bold></td><td align="left" rowspan="1" colspan="1"><bold>Hypo (</bold><xref rid="t001fn005" ref-type="table-fn">****</xref><bold>)</bold></td><td align="left" rowspan="1" colspan="1"><bold>unchanged</bold></td><td align="left" rowspan="1" colspan="1"><bold>Hypo (</bold><xref rid="t001fn003" ref-type="table-fn">**</xref><bold>)</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>cg09993699</bold></td><td align="left" rowspan="1" colspan="1"><bold>Probe 8</bold></td><td align="left" rowspan="1" colspan="1"><bold>Hypo (</bold><xref rid="t001fn005" ref-type="table-fn">****</xref><bold>)</bold></td><td align="left" rowspan="1" colspan="1"><bold>Hypo (</bold><xref rid="t001fn005" ref-type="table-fn">****</xref><bold>)</bold></td><td align="left" rowspan="1" colspan="1"><bold>unchanged</bold></td><td align="left" rowspan="1" colspan="1"><bold>Hypo (</bold><xref rid="t001fn005" ref-type="table-fn">****</xref><bold>)</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>cg20092122</bold></td><td align="left" rowspan="1" colspan="1"><bold>Probe 9</bold></td><td align="left" rowspan="1" colspan="1"><bold>Hypo (</bold><xref rid="t001fn005" ref-type="table-fn">****</xref><bold>)</bold></td><td align="left" rowspan="1" colspan="1"><bold>Hypo (</bold><xref rid="t001fn002" ref-type="table-fn">*</xref><bold>)</bold></td><td align="left" rowspan="1" colspan="1"><bold>unchanged</bold></td><td align="left" rowspan="1" colspan="1"><bold>Hypo (</bold><xref rid="t001fn004" ref-type="table-fn">***</xref><bold>)</bold></td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t001fn001"><p>* Is degree of hyper- or hypo-methylation based on statistical significance relative to normalbreast tissues (unpaired t test with Welch's correction). P value (*), where:</p></fn><fn id="t001fn002"><p>* is p &#x0003c; 0.02,</p></fn><fn id="t001fn003"><p>** is p &#x0003c; 0.003,</p></fn><fn id="t001fn004"><p>*** is p &#x0003c; 0.0005 and</p></fn><fn id="t001fn005"><p>**** is p &#x0003c; 0.0001.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec017"><title>BST-2 mRNA expression correlates with DNA hypomethylation in breast cancer epithelial cells</title><p>In breast carcinomas, neoplastic epithelial cells coexist and interact with various stromal cells that together create the tumor microenvironment. While neoplastic epithelial cells have higher BST-2 mRNA compared to normal cells, there was no difference in the expression pattern of another antiviral gene called Apobec3G (A3G) in these epithelial cells (<xref rid="pone.0123931.g005" ref-type="fig">Fig 5A</xref>). This data support the preposition that neoplastic epithelial cells are the source of elevated BST-2 expression in tumors [<xref rid="pone.0123931.ref004" ref-type="bibr">4</xref>]. Analysis of the stromal cells for BST-2 and A3G expression confirmed that cancer epithelial cells are the source of elevated BST-2 in tumors (<xref rid="pone.0123931.g005" ref-type="fig">Fig 5B</xref>). On the basis of this finding, we assessed correlation in patterns of BST-2 mRNA expression and <italic>BST-2</italic> methylation in well-established breast cancer cell lines downloaded from GEO dataset GSE10797 [<xref rid="pone.0123931.ref031" ref-type="bibr">31</xref>]. Our analysis revealed that elevated, levels of BST-2 mRNA varied among different breast cancer cell lines; with MCF-7 cells expressing the least BST-2 mRNA (<xref rid="pone.0123931.g005" ref-type="fig">Fig 5C</xref>, bar graph (GSE10797) and line graph (GSE49794)). Importantly, the relative levels of BST-2 expression are similar between the two datasets used (<xref rid="pone.0123931.g005" ref-type="fig">Fig 5C</xref>, bar and line graphs). As expected, level of BST-2 expression was inversely correlated to the methylation status of CpG sites represented by probes 3 to 9 (Fig <xref rid="pone.0123931.g005" ref-type="fig">5C</xref> line graph, and <xref rid="pone.0123931.g005" ref-type="fig">5D</xref>). As such, MCF-7 cells which have the lowest BST-2 mRNA levels (<xref rid="pone.0123931.g005" ref-type="fig">Fig 5C</xref>) have the highest methylation beta-values on probes 3 to 9 than any of the other cell lines (Fig <xref rid="pone.0123931.g005" ref-type="fig">5D</xref> and <xref rid="pone.0123931.g005" ref-type="fig">5E</xref>). Remarkably, high BST-2-expressing luminal A T47D cells, triple-negative MDA-MB-231 cells and basal SUM-159 cells are significantly hypomethylated (methylation beta-values of 0.21127, 0.10207 and 0.10295, respectively) on CpG sites corresponding to probe 9 (<xref rid="pone.0123931.g005" ref-type="fig">Fig 5D</xref>).</p><fig id="pone.0123931.g005" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0123931.g005</object-id><label>Fig 5</label><caption><title>BST-2 expression inversely correlates with methylation density in neoplastic breast epithelial cell lines.</title><p>(A) BST-2 and APOBEC3G (A3G) transcript levels in normal and tumor epithelial cells from patients with breast cancer. (B) BST-2 and A3G transcripts present in normal and tumor stromal cells of patients with breast cancer. Data were downloaded from GEO dataset GSE10797. (C) BST-2 expression levels among two luminal A cell lines (MCF-7 and T47D) and two triple-negative cell lines (MDA-MB-231 and SUM-159). Data were acquired from GEO dataset GSE41313 (bar graph, Log2 units) and GEO dataset GSE45732 (gray line graph, RPKM units). (D) Methylation status among different CpG sites from the breast cancer cell lines whose mRNA is presented in line graph in 5C. Data acquired from GEO dataset GSE49794. (E) BST-2 expression versus methylation plot among the four breast cancer cell lines presented in 5C (line graph) and 5D. Methylation beta-value is an average of probes 3 to 9 &#x000b1; SEM. Methylation data was from GSE49794 (beta-value) and expression data was from GSE45732, a superseries from the same cells. Significance was taken at P&#x0003c;0.05 (*). n.s = not significant. Error bars correspond to standard error of the mean (SEM).</p></caption><graphic xlink:href="pone.0123931.g005"/></fig><p>Moreover, the average methylation beta-value for probes 3 to 9 was inversely correlated to their corresponding BST-2 mRNA levels among all breast cancer cell lines analyzed (<xref rid="pone.0123931.g005" ref-type="fig">Fig 5E</xref>), providing additional support for a link between BST-2 expression and methylation status. Together with tumor data presented in <xref rid="pone.0123931.g004" ref-type="fig">Fig 4</xref> and <xref rid="pone.0123931.t001" ref-type="table">Table 1</xref>, it appears that BST-2 expression is increased by hypomethylation of CpG sites adjacent and downstream of the BST-2 TSS. Furthermore, in aggressive breast cancers and cancer cell lines, such as basal and triple-negative tumors, <italic>BST-2</italic> is hypomethylated at CpG sites downstream of the BST-2 TSS.</p></sec><sec id="sec018"><title>Cancer cells with elevated BST-2 levels are unresponsive to 5-azacytidine induced BST-2 DNA demethylation</title><p>2&#x02032;-deoxy-5-azacytidine (decitabine, DAC) is a deoxycytidine which incorporates into replicating DNA and prevents DNA methylation, thus, resulting in DNA hypomethylation and upregulation of gene expression. Since levels of BST-2 expression varies among cancer cells, we predicted that treatment with demethylating agents will further elevate BST-2 expression in cancer cells such as MCF-7 that express low BST-2, but that such treatment will have no effect on high BST-2 expressing cells. For this purpose, we used GEO datasets GSE28976 [<xref rid="pone.0123931.ref043" ref-type="bibr">43</xref>] and GSE36683 [<xref rid="pone.0123931.ref044" ref-type="bibr">44</xref>] (for MCF-7s only) to analyze the effect of DAC on <italic>BST-2</italic> methylation in several human breast cancer cell lines. We found that DAC treatment of normal breast cell line HB2 and low BST-2-expressing luminal A cell line MCF-7 led to increased BST-2 mRNA expression (<xref rid="pone.0123931.g006" ref-type="fig">Fig 6A</xref>). However, DAC-treated high BST-2-expressing HER2 SK-BR-3 and triple-negative MDA-MB-231 cells did not show any increase in BST-2 levels (<xref rid="pone.0123931.g006" ref-type="fig">Fig 6A</xref>). Importantly, mRNA levels of the tumor suppressor gene claudin-6 (CLDN6) reported to be increased in breast cancer cells upon DAC treatment [<xref rid="pone.0123931.ref051" ref-type="bibr">51</xref>] were induced in all cell types regardless of their subtype classification, while GAPDH mRNA, a house keeping gene did not change following DAC treatment (<xref rid="pone.0123931.g006" ref-type="fig">Fig 6A</xref>).</p><fig id="pone.0123931.g006" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0123931.g006</object-id><label>Fig 6</label><caption><title>The effect of demethylating agents on BST-2 expression.</title><p>(A) Meta-analysis of BST-2, Claudin-6 (CLDN6), and GAPDH expression levels in HB2, SK-BR-3, MDA-MB-231 cells (downloaded from GEO dataset GSE28976) and MCF-7 cells (downloaded from GEO dataset GSE36683) following treatment with 5-aza-2&#x02019;-deoxycytidine (DAC). MCF-7 data was acquired from a different dataset, hence the difference in expression values. (B) BST-2, Claudin-6 (CLDN6), and GAPDH expression levels in HMLE, MCF-7, SK-BR-3, and MDA-MB-231 cells following treatment with DMSO (vehicle) or 1 uM of 5-azacytidine (5-AzaC) for 5 days. (C) BST-2 surface expression from HMLE, MCF-7, SK-BR-3 and MDA-MB-231 cells treated with DMSO (vehicle) or 1 uM of 5-azacytidine (5-AzaC) for 5 days as determined by flow cytometry. Numbers in parenthesis correspond to BST-2 expression presented as a percentage. Significance was taken at P&#x0003c;0.05 (*). Error bars correspond to SEM. n.s = not significant.</p></caption><graphic xlink:href="pone.0123931.g006"/></fig><p>GEO data were validated by treating cells with the nucleoside analogue 5-azacytidine (azacytidine, 5-AZaC) and analyzing BST-2, CLDN6 and GAPDH mRNA levels (<xref rid="pone.0123931.g006" ref-type="fig">Fig 6B</xref>) and BST-2 protein levels (<xref rid="pone.0123931.g006" ref-type="fig">Fig 6C</xref>). In agreement with the GEO datasets in <xref rid="pone.0123931.g006" ref-type="fig">Fig 6A</xref>, HMLE (normal breast epithelial cell line) and MCF-7 cells treated with 5-AzaC showed a significant increase in BST-2 levels both at the RNA and protein levels (Fig <xref rid="pone.0123931.g006" ref-type="fig">6B</xref> and <xref rid="pone.0123931.g006" ref-type="fig">6C</xref>), while levels of BST-2 mRNA and protein following 5-AzaC treatment were unchanged in high BST-2-expressing HER2 SK-BR-3 and triple negative MDA-MB-231 cells (Fig <xref rid="pone.0123931.g006" ref-type="fig">6B</xref> and <xref rid="pone.0123931.g006" ref-type="fig">6C</xref>). As expected, CLDN6 was induced in all cell types upon 5-AzaC treatment (<xref rid="pone.0123931.g006" ref-type="fig">Fig 6B</xref>), but GAPDH did not change (<xref rid="pone.0123931.g006" ref-type="fig">Fig 6B</xref>). These results suggest that DAC/5-AzaC does not impact BST-2 expression in cancer cells with elevated BST-2 [<xref rid="pone.0123931.ref052" ref-type="bibr">52</xref>,<xref rid="pone.0123931.ref053" ref-type="bibr">53</xref>].</p></sec></sec><sec sec-type="conclusions" id="sec019"><title>Discussion</title><p>DNA demethylation was the first described epigenetic modification observed in various human cancers compared to normal tissues [<xref rid="pone.0123931.ref054" ref-type="bibr">54</xref>]. Cancer-linked DNA demethylation is associated with metastases of primary tumors [<xref rid="pone.0123931.ref055" ref-type="bibr">55</xref>,<xref rid="pone.0123931.ref056" ref-type="bibr">56</xref>] and is as prevalent as cancer-associated DNA hypermethylation. In cancer genomes, DNA hypermethylation is thought to occur in the promoter regions of tumor suppressor genes, which may lead to silencing of these tumor suppressors [<xref rid="pone.0123931.ref057" ref-type="bibr">57</xref>]. In contrast, DNA hypomethylation frequently occurs in DNA repeats, resulting in genomic instability and mutation in cancer genomes [<xref rid="pone.0123931.ref058" ref-type="bibr">58</xref>&#x02013;<xref rid="pone.0123931.ref060" ref-type="bibr">60</xref>]. It has been suggested that hypomethylation of immunity-related genes, such as BST-2 may promote carcinogenesis. As such, promoter hypomethylation of IL-10 activates its expression and inhibits the generation of immune response against breast cancer [<xref rid="pone.0123931.ref061" ref-type="bibr">61</xref>], while hypomethylation of the immunogenic antigen SPAN-Xb may result in de novo B-cell response in myeloma cells [<xref rid="pone.0123931.ref062" ref-type="bibr">62</xref>]. In this study, we conducted meta-analysis of the methylation status of the BST-2 gene because BST-2 has been associated with development and progression of breast cancer in vivo [<xref rid="pone.0123931.ref004" ref-type="bibr">4</xref>]. The mechanism for the role of BST-2 in the evolution/progression of breast carcinogenesis is still poorly understood. Nevertheless, RNAi-mediated downregulation of BST-2 increases the survival of tumor-bearing mice [<xref rid="pone.0123931.ref004" ref-type="bibr">4</xref>], suggesting therapeutic significance.</p><p>Meta-analyses of human epidemiological data revealed that in breast tumors and neoplastic epithelial cells, BST-2 expression is epigenetically regulated by DNA demethylation. There are unique CpG sites corresponding to probes 3 to 9 from the Human Methylation 450 array and proximal to the BST-2 gene TSS that were demethylated across all breast tumor types (<xref rid="pone.0123931.g004" ref-type="fig">Fig 4A</xref>), irrespective of their subtype classification. In luminal B tumors, CpGs represented by probes 3 to 9 are significantly hypomethylated compared to normal tissues (<xref rid="pone.0123931.t001" ref-type="table">Table 1</xref>); this observation is interesting given that this cancer subtype is considered to have a hypermethylated phenotype among breast cancer subtypes [<xref rid="pone.0123931.ref063" ref-type="bibr">63</xref>]. The CpG sites corresponding to probes 8 and 9 that are downstream and distal to BST-2 TSS were of significance to the triple-negative tumor subtype, as its methylation beta-value was lower compared to other subtypes (Figs <xref rid="pone.0123931.g004" ref-type="fig">4A</xref>, <xref rid="pone.0123931.g004" ref-type="fig">4I</xref>, <xref rid="pone.0123931.g004" ref-type="fig">4J</xref>, <xref rid="pone.0123931.g005" ref-type="fig">5D</xref>, and <xref rid="pone.0123931.g005" ref-type="fig">5E</xref>). In contrast, the hypermethylated CpG sites represented by probes 1 and 2 that are upstream and distal to BST-2 TSS may have little or no effect on BST-2 regulation (Fig <xref rid="pone.0123931.g004" ref-type="fig">4A</xref> to <xref rid="pone.0123931.g004" ref-type="fig">4C</xref>).</p><p>Remarkably, the demethylated CpG sites represented by probes 3 to 7 are largely located adjacent to transcription factor binding sites in the BST-2 gene, including those of nuclear factor of activated T-cells (NF-AT), interferon regulatory factor (IRF) [<xref rid="pone.0123931.ref012" ref-type="bibr">12</xref>,<xref rid="pone.0123931.ref064" ref-type="bibr">64</xref>], signal transducers and activators of transcription (STAT), and nuclear factor kappa B (NF-&#x0043a;B) [<xref rid="pone.0123931.ref065" ref-type="bibr">65</xref>]. This observation is interesting because DNA methylation controls gene transcription through interference with the ability of transcription factors to bind to DNA [<xref rid="pone.0123931.ref066" ref-type="bibr">66</xref>]. A phenomenon that could partially explain the significant inverse relationship between BST-2 expression and BST-2 DNA methylation observed on probes 3 to 7. In addition, the inability of high BST-2 expressing MDA-MB-231 and SK-BR-3 cells to respond to DAC- or 5-AzaC-mediated induction of BST-2 expression suggests that high BST-2-expressing aggressive breast cancers at some point may have lost methylation-dependent regulation of BST-2 transcription which results in BST-2 overexpression and promotion of breast malignancy [<xref rid="pone.0123931.ref004" ref-type="bibr">4</xref>]. An alternative explanation could be that demethylating agents had a stabilizing effect on BST-2 in these cells, a phenomenon reported previously for MATN4 and CTSL2 unresponsiveness to 5-AzaC [<xref rid="pone.0123931.ref052" ref-type="bibr">52</xref>,<xref rid="pone.0123931.ref053" ref-type="bibr">53</xref>].</p><p>Examples of tumor-related overexpressed genes which become promoter hypomethylated during carcinogenesis includes, but not limited to, Sonic Hedgehog [<xref rid="pone.0123931.ref067" ref-type="bibr">67</xref>], P-cadherin [<xref rid="pone.0123931.ref068" ref-type="bibr">68</xref>], and CDH3 [<xref rid="pone.0123931.ref069" ref-type="bibr">69</xref>], as well as MATN4 and CTSL2 [<xref rid="pone.0123931.ref052" ref-type="bibr">52</xref>,<xref rid="pone.0123931.ref053" ref-type="bibr">53</xref>], supporting the data reported here for BST-2. Indeed, BST-2 overexpression due to DNA hypomethylation has been reported for glioblastoma [<xref rid="pone.0123931.ref070" ref-type="bibr">70</xref>] and lupus [<xref rid="pone.0123931.ref071" ref-type="bibr">71</xref>]. Patients with lupus presented with BST-2 hypomethylation on probes 1 to 7 compared to the controls, pointing to a common mechanism of methylation-dependent BST-2 regulation.</p><p>However, we cannot rule out other epigenetic-dependent or&#x02014;independent sources of BST-2 regulation such as gene amplification, histone posttranslational modifications, increased translation of BST-2 or a decrease in the rate of BST-2 degradation or turnover. Further research is warranted to determine whether there are other mechanisms controlling BST-2 overexpression in breast cancer and whether methylation changes regulate BST-2 expression in other cancers including those in which BST-2 levels are unchanged (<xref rid="pone.0123931.g001" ref-type="fig">Fig 1A</xref>) or suppressed (<xref rid="pone.0123931.g001" ref-type="fig">Fig 1B</xref>) in tumor tissues compared to their corresponding normal tissues. Additionally, it is of interest to determine how changes in BST-2 DNA methylation pattern relate to the molecular pathology in breast cancer initiation, progression, and metastasis.</p></sec><sec sec-type="conclusions" id="sec020"><title>Conclusions</title><p>We conclude that a greater frequency of <italic>BST-2</italic> hypomethylation was observed in breast cancer tissues and cells compared to normal breast tissues and cells. Therefore, BST-2 overexpression from DNA hypomethylation could influence breast carcinogenesis and could predict breast cancer prognosis or therapeutic response.</p></sec></body><back><ack><p>The authors are grateful to Bryson Okeoma of University of Iowa for criticizing this manuscript and to Adam Dupuy of the University of Iowa for assistance in data acquisition.</p></ack><ref-list><title>References</title><ref id="pone.0123931.ref001"><label>1</label><mixed-citation publication-type="journal"><name><surname>Yersal</surname><given-names>O</given-names></name>, <name><surname>Barutca</surname><given-names>S</given-names></name> (<year>2014</year>) <article-title>Biological subtypes of breast cancer: Prognostic and therapeutic implications</article-title>. <source>World J Clin Oncol</source><volume>5</volume>: <fpage>412</fpage>&#x02013;<lpage>424</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.5306/wjco.v5.i3.412">10.5306/wjco.v5.i3.412</ext-link></comment>
<?supplied-pmid 25114856?><pub-id pub-id-type="pmid">25114856</pub-id></mixed-citation></ref><ref id="pone.0123931.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>Tran</surname><given-names>B</given-names></name>, <name><surname>Bedard</surname><given-names>PL</given-names></name> (<year>2011</year>) <article-title>Luminal-B breast cancer and novel therapeutic targets</article-title>. <source>Breast Cancer Res</source>
<volume>13</volume>: <fpage>221</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/bcr2904">10.1186/bcr2904</ext-link></comment>
<?supplied-pmid 22217398?><pub-id pub-id-type="pmid">22217398</pub-id></mixed-citation></ref><ref id="pone.0123931.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>Cheang</surname><given-names>MC</given-names></name>, <name><surname>Voduc</surname><given-names>D</given-names></name>, <name><surname>Bajdik</surname><given-names>C</given-names></name>, <name><surname>Leung</surname><given-names>S</given-names></name>, <name><surname>McKinney</surname><given-names>S</given-names></name>, <name><surname>Chia</surname><given-names>SK</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype</article-title>. <source>Clin Cancer Res</source>
<volume>14</volume>: <fpage>1368</fpage>&#x02013;<lpage>1376</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1158/1078-0432.CCR-07-1658">10.1158/1078-0432.CCR-07-1658</ext-link></comment>
<?supplied-pmid 18316557?><pub-id pub-id-type="pmid">18316557</pub-id></mixed-citation></ref><ref id="pone.0123931.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Mahauad-Fernandez</surname><given-names>WD</given-names></name>, <name><surname>DeMali</surname><given-names>KA</given-names></name>, <name><surname>Olivier</surname><given-names>AK</given-names></name>, <name><surname>Okeoma</surname><given-names>CM</given-names></name> (<year>2014</year>) <article-title>Bone marrow stromal antigen 2 expressed in cancer cells promotes mammary tumor growth and metastasis</article-title>. <source>Breast Cancer Res</source>
<volume>16</volume>: <fpage>493</fpage>
<?supplied-pmid 25499888?><pub-id pub-id-type="pmid">25499888</pub-id></mixed-citation></ref><ref id="pone.0123931.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Sauter</surname><given-names>D</given-names></name> (<year>2014</year>) <article-title>Counteraction of the multifunctional restriction factor tetherin</article-title>. <source>Front Microbiol</source>
<volume>5</volume>: <fpage>163</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3389/fmicb.2014.00163">10.3389/fmicb.2014.00163</ext-link></comment>
<?supplied-pmid 24782851?><pub-id pub-id-type="pmid">24782851</pub-id></mixed-citation></ref><ref id="pone.0123931.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Cole</surname><given-names>G</given-names></name>, <name><surname>Simonetti</surname><given-names>K</given-names></name>, <name><surname>Ademi</surname><given-names>I</given-names></name>, <name><surname>Sharpe</surname><given-names>S</given-names></name> (<year>2012</year>) <article-title>Dimerization of the transmembrane domain of human tetherin in membrane mimetic environments</article-title>. <source>Biochemistry</source>
<volume>51</volume>: <fpage>5033</fpage>&#x02013;<lpage>5040</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1021/bi201747t">10.1021/bi201747t</ext-link></comment>
<?supplied-pmid 22667354?><pub-id pub-id-type="pmid">22667354</pub-id></mixed-citation></ref><ref id="pone.0123931.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>Kupzig</surname><given-names>S</given-names></name>, <name><surname>Korolchuk</surname><given-names>V</given-names></name>, <name><surname>Rollason</surname><given-names>R</given-names></name>, <name><surname>Sugden</surname><given-names>A</given-names></name>, <name><surname>Wilde</surname><given-names>A</given-names></name>, <name><surname>Banting</surname><given-names>G</given-names></name> (<year>2003</year>) <article-title>Bst-2/HM1.24 is a raft-associated apical membrane protein with an unusual topology</article-title>. <source>Traffic</source>
<volume>4</volume>: <fpage>694</fpage>&#x02013;<lpage>709</lpage>. <?supplied-pmid 12956872?><pub-id pub-id-type="pmid">12956872</pub-id></mixed-citation></ref><ref id="pone.0123931.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Goto</surname><given-names>T</given-names></name>, <name><surname>Kennel</surname><given-names>SJ</given-names></name>, <name><surname>Abe</surname><given-names>M</given-names></name>, <name><surname>Takishita</surname><given-names>M</given-names></name>, <name><surname>Kosaka</surname><given-names>M</given-names></name>, <name><surname>Solomon</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>1994</year>) <article-title>A novel membrane antigen selectively expressed on terminally differentiated human B cells</article-title>. <source>Blood</source>
<volume>84</volume>: <fpage>1922</fpage>&#x02013;<lpage>1930</lpage>. <?supplied-pmid 8080996?><pub-id pub-id-type="pmid">8080996</pub-id></mixed-citation></ref><ref id="pone.0123931.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Neil</surname><given-names>SJ</given-names></name>, <name><surname>Zang</surname><given-names>T</given-names></name>, <name><surname>Bieniasz</surname><given-names>PD</given-names></name> (<year>2008</year>) <article-title>Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu</article-title>. <source>Nature</source>
<volume>451</volume>: <fpage>425</fpage>&#x02013;<lpage>430</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nature06553">10.1038/nature06553</ext-link></comment>
<?supplied-pmid 18200009?><pub-id pub-id-type="pmid">18200009</pub-id></mixed-citation></ref><ref id="pone.0123931.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Van Damme</surname><given-names>N</given-names></name>, <name><surname>Goff</surname><given-names>D</given-names></name>, <name><surname>Katsura</surname><given-names>C</given-names></name>, <name><surname>Jorgenson</surname><given-names>RL</given-names></name>, <name><surname>Mitchell</surname><given-names>R</given-names></name>, <name><surname>Johnson</surname><given-names>MC</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein</article-title>. <source>Cell Host Microbe</source>
<volume>3</volume>: <fpage>245</fpage>&#x02013;<lpage>252</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.chom.2008.03.001">10.1016/j.chom.2008.03.001</ext-link></comment>
<?supplied-pmid 18342597?><pub-id pub-id-type="pmid">18342597</pub-id></mixed-citation></ref><ref id="pone.0123931.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Jones</surname><given-names>PH</given-names></name>, <name><surname>Mehta</surname><given-names>HV</given-names></name>, <name><surname>Maric</surname><given-names>M</given-names></name>, <name><surname>Roller</surname><given-names>RJ</given-names></name>, <name><surname>Okeoma</surname><given-names>CM</given-names></name> (<year>2012</year>) <article-title>Bone marrow stromal cell antigen 2 (BST-2) restricts mouse mammary tumor virus (MMTV) replication in vivo</article-title>. <source>Retrovirology</source>
<volume>9</volume>: <fpage>10</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/1742-4690-9-10">10.1186/1742-4690-9-10</ext-link></comment>
<?supplied-pmid 22284121?><pub-id pub-id-type="pmid">22284121</pub-id></mixed-citation></ref><ref id="pone.0123931.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Jones</surname><given-names>PH</given-names></name>, <name><surname>Maric</surname><given-names>M</given-names></name>, <name><surname>Madison</surname><given-names>MN</given-names></name>, <name><surname>Maury</surname><given-names>W</given-names></name>, <name><surname>Roller</surname><given-names>RJ</given-names></name>, <name><surname>Okeoma</surname><given-names>CM</given-names></name> (<year>2013</year>) <article-title>BST-2/tetherin-mediated restriction of chikungunya (CHIKV) VLP budding is counteracted by CHIKV non-structural protein 1 (nsP1)</article-title>. <source>Virology</source>
<volume>438</volume>: <fpage>37</fpage>&#x02013;<lpage>49</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.virol.2013.01.010">10.1016/j.virol.2013.01.010</ext-link></comment>
<?supplied-pmid 23411007?><pub-id pub-id-type="pmid">23411007</pub-id></mixed-citation></ref><ref id="pone.0123931.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Mahauad-Fernandez</surname><given-names>WD</given-names></name>, <name><surname>Jones</surname><given-names>PH</given-names></name>, <name><surname>Okeoma</surname><given-names>CM</given-names></name> (<year>2014</year>) <article-title>Critical role for BST-2 in acute Chikungunya virus infection</article-title>. <source>J Gen Virol</source>.</mixed-citation></ref><ref id="pone.0123931.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>SX</given-names></name>, <name><surname>Barrett</surname><given-names>BS</given-names></name>, <name><surname>Heilman</surname><given-names>KJ</given-names></name>, <name><surname>Messer</surname><given-names>RJ</given-names></name>, <name><surname>Liberatore</surname><given-names>RA</given-names></name>, <name><surname>Bieniasz</surname><given-names>PD</given-names></name>, <etal>et al</etal> (<year>2014</year>) <article-title>Tetherin promotes the innate and adaptive cell-mediated immune response against retrovirus infection in vivo</article-title>. <source>J Immunol</source>
<volume>193</volume>: <fpage>306</fpage>&#x02013;<lpage>316</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.4049/jimmunol.1400490">10.4049/jimmunol.1400490</ext-link></comment>
<?supplied-pmid 24872193?><pub-id pub-id-type="pmid">24872193</pub-id></mixed-citation></ref><ref id="pone.0123931.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>Galao</surname><given-names>RP</given-names></name>, <name><surname>Le Tortorec</surname><given-names>A</given-names></name>, <name><surname>Pickering</surname><given-names>S</given-names></name>, <name><surname>Kueck</surname><given-names>T</given-names></name>, <name><surname>Neil</surname><given-names>SJ</given-names></name> (<year>2012</year>) <article-title>Innate sensing of HIV-1 assembly by Tetherin induces NFkappaB-dependent proinflammatory responses</article-title>. <source>Cell Host Microbe</source>
<volume>12</volume>: <fpage>633</fpage>&#x02013;<lpage>644</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.chom.2012.10.007">10.1016/j.chom.2012.10.007</ext-link></comment>
<?supplied-pmid 23159053?><pub-id pub-id-type="pmid">23159053</pub-id></mixed-citation></ref><ref id="pone.0123931.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Tokarev</surname><given-names>A</given-names></name>, <name><surname>Suarez</surname><given-names>M</given-names></name>, <name><surname>Kwan</surname><given-names>W</given-names></name>, <name><surname>Fitzpatrick</surname><given-names>K</given-names></name>, <name><surname>Singh</surname><given-names>R</given-names></name>, <name><surname>Guatelli</surname><given-names>J</given-names></name> (<year>2013</year>) <article-title>Stimulation of NF-kappaB activity by the HIV restriction factor BST2</article-title>. <source>J Virol</source>
<volume>87</volume>: <fpage>2046</fpage>&#x02013;<lpage>2057</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/JVI.02272-12">10.1128/JVI.02272-12</ext-link></comment>
<?supplied-pmid 23221546?><pub-id pub-id-type="pmid">23221546</pub-id></mixed-citation></ref><ref id="pone.0123931.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>Arias</surname><given-names>JF</given-names></name>, <name><surname>Heyer</surname><given-names>LN</given-names></name>, <name><surname>von Bredow</surname><given-names>B</given-names></name>, <name><surname>Weisgrau</surname><given-names>KL</given-names></name>, <name><surname>Moldt</surname><given-names>B</given-names></name>, <name><surname>Burton</surname><given-names>DR</given-names></name>, <etal>et al</etal> (<year>2014</year>) <article-title>Tetherin antagonism by Vpu protects HIV-infected cells from antibody-dependent cell-mediated cytotoxicity</article-title>. <source>Proc Natl Acad Sci U S A</source>
<volume>111</volume>: <fpage>6425</fpage>&#x02013;<lpage>6430</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1073/pnas.1321507111">10.1073/pnas.1321507111</ext-link></comment>
<?supplied-pmid 24733916?><pub-id pub-id-type="pmid">24733916</pub-id></mixed-citation></ref><ref id="pone.0123931.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>Pham</surname><given-names>TN</given-names></name>, <name><surname>Lukhele</surname><given-names>S</given-names></name>, <name><surname>Hajjar</surname><given-names>F</given-names></name>, <name><surname>Routy</surname><given-names>JP</given-names></name>, <name><surname>Cohen</surname><given-names>EA</given-names></name> (<year>2014</year>) <article-title>HIV Nef and Vpu protect HIV-infected CD4+ T cells from antibody-mediated cell lysis through down-modulation of CD4 and BST2</article-title>. <source>Retrovirology</source>
<volume>11</volume>: <fpage>15</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/1742-4690-11-15">10.1186/1742-4690-11-15</ext-link></comment>
<?supplied-pmid 24498878?><pub-id pub-id-type="pmid">24498878</pub-id></mixed-citation></ref><ref id="pone.0123931.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Alvarez</surname><given-names>RA</given-names></name>, <name><surname>Hamlin</surname><given-names>RE</given-names></name>, <name><surname>Monroe</surname><given-names>A</given-names></name>, <name><surname>Moldt</surname><given-names>B</given-names></name>, <name><surname>Hotta</surname><given-names>MT</given-names></name>, <name><surname>Rodriguez Caprio</surname><given-names>G</given-names></name>, <etal>et al</etal> (<year>2014</year>) <article-title>HIV-1 Vpu Antagonism of Tetherin Inhibits Antibody-Dependent Cellular Cytotoxic Responses by Natural Killer Cells</article-title>. <source>J Virol</source>
<volume>88</volume>: <fpage>6031</fpage>&#x02013;<lpage>6046</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/JVI.00449-14">10.1128/JVI.00449-14</ext-link></comment>
<?supplied-pmid 24623433?><pub-id pub-id-type="pmid">24623433</pub-id></mixed-citation></ref><ref id="pone.0123931.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Silveira</surname><given-names>NJ</given-names></name>, <name><surname>Varuzza</surname><given-names>L</given-names></name>, <name><surname>Machado-Lima</surname><given-names>A</given-names></name>, <name><surname>Lauretto</surname><given-names>MS</given-names></name>, <name><surname>Pinheiro</surname><given-names>DG</given-names></name>, <name><surname>Rodrigues</surname><given-names>RV</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>Searching for molecular markers in head and neck squamous cell carcinomas (HNSCC) by statistical and bioinformatic analysis of larynx-derived SAGE libraries</article-title>. <source>BMC Med Genomics</source>
<volume>1</volume>: <fpage>56</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/1755-8794-1-56">10.1186/1755-8794-1-56</ext-link></comment>
<?supplied-pmid 19014460?><pub-id pub-id-type="pmid">19014460</pub-id></mixed-citation></ref><ref id="pone.0123931.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Fang</surname><given-names>KH</given-names></name>, <name><surname>Kao</surname><given-names>HK</given-names></name>, <name><surname>Chi</surname><given-names>LM</given-names></name>, <name><surname>Liang</surname><given-names>Y</given-names></name>, <name><surname>Liu</surname><given-names>SC</given-names></name>, <name><surname>Hseuh</surname><given-names>C</given-names></name>, <etal>et al</etal> (<year>2014</year>) <article-title>Overexpression of BST2 is associated with nodal metastasis and poorer prognosis in oral cavity cancer</article-title>. <source>Laryngoscope</source>.</mixed-citation></ref><ref id="pone.0123931.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>Wainwright</surname><given-names>DA</given-names></name>, <name><surname>Balyasnikova</surname><given-names>IV</given-names></name>, <name><surname>Han</surname><given-names>Y</given-names></name>, <name><surname>Lesniak</surname><given-names>MS</given-names></name> (<year>2011</year>) <article-title>The expression of BST2 in human and experimental mouse brain tumors</article-title>. <source>Exp Mol Pathol</source>
<volume>91</volume>: <fpage>440</fpage>&#x02013;<lpage>446</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.yexmp.2011.04.012">10.1016/j.yexmp.2011.04.012</ext-link></comment>
<?supplied-pmid 21565182?><pub-id pub-id-type="pmid">21565182</pub-id></mixed-citation></ref><ref id="pone.0123931.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>W</given-names></name>, <name><surname>Nishioka</surname><given-names>Y</given-names></name>, <name><surname>Ozaki</surname><given-names>S</given-names></name>, <name><surname>Jalili</surname><given-names>A</given-names></name>, <name><surname>Verma</surname><given-names>VK</given-names></name>, <name><surname>Hanibuchi</surname><given-names>M</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Chimeric and humanized anti-HM1.24 antibodies mediate antibody-dependent cellular cytotoxicity against lung cancer cells</article-title>. <source>Lung Cancer</source>
<volume>63</volume>: <fpage>23</fpage>&#x02013;<lpage>31</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.lungcan.2008.04.009">10.1016/j.lungcan.2008.04.009</ext-link></comment>
<?supplied-pmid 18524412?><pub-id pub-id-type="pmid">18524412</pub-id></mixed-citation></ref><ref id="pone.0123931.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>Wong</surname><given-names>YF</given-names></name>, <name><surname>Cheung</surname><given-names>TH</given-names></name>, <name><surname>Lo</surname><given-names>KW</given-names></name>, <name><surname>Yim</surname><given-names>SF</given-names></name>, <name><surname>Siu</surname><given-names>NS</given-names></name>, <name><surname>Chan</surname><given-names>SC</given-names></name>, <etal>et al</etal> (<year>2007</year>) <article-title>Identification of molecular markers and signaling pathway in endometrial cancer in Hong Kong Chinese women by genome-wide gene expression profiling</article-title>. <source>Oncogene</source>
<volume>26</volume>: <fpage>1971</fpage>&#x02013;<lpage>1982</lpage>. <?supplied-pmid 17043662?><pub-id pub-id-type="pmid">17043662</pub-id></mixed-citation></ref><ref id="pone.0123931.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Schliemann</surname><given-names>C</given-names></name>, <name><surname>Roesli</surname><given-names>C</given-names></name>, <name><surname>Kamada</surname><given-names>H</given-names></name>, <name><surname>Borgia</surname><given-names>B</given-names></name>, <name><surname>Fugmann</surname><given-names>T</given-names></name>, <name><surname>Klapper</surname><given-names>W</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>In vivo biotinylation of the vasculature in B-cell lymphoma identifies BST-2 as a target for antibody-based therapy</article-title>. <source>Blood</source>
<volume>115</volume>: <fpage>736</fpage>&#x02013;<lpage>744</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1182/blood-2009-08-239004">10.1182/blood-2009-08-239004</ext-link></comment>
<?supplied-pmid 19903902?><pub-id pub-id-type="pmid">19903902</pub-id></mixed-citation></ref><ref id="pone.0123931.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>Cai</surname><given-names>D</given-names></name>, <name><surname>Cao</surname><given-names>J</given-names></name>, <name><surname>Li</surname><given-names>Z</given-names></name>, <name><surname>Zheng</surname><given-names>X</given-names></name>, <name><surname>Yao</surname><given-names>Y</given-names></name>, <name><surname>Li</surname><given-names>W</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Up-regulation of bone marrow stromal protein 2 (BST2) in breast cancer with bone metastasis</article-title>. <source>BMC Cancer</source>
<volume>9</volume>: <fpage>102</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/1471-2407-9-102">10.1186/1471-2407-9-102</ext-link></comment>
<?supplied-pmid 19338666?><pub-id pub-id-type="pmid">19338666</pub-id></mixed-citation></ref><ref id="pone.0123931.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>Ono</surname><given-names>K</given-names></name>, <name><surname>Ohtomo</surname><given-names>T</given-names></name>, <name><surname>Yoshida</surname><given-names>K</given-names></name>, <name><surname>Yoshimura</surname><given-names>Y</given-names></name>, <name><surname>Kawai</surname><given-names>S</given-names></name>, <name><surname>Koishihara</surname><given-names>Y</given-names></name>, <etal>et al</etal> (<year>1999</year>) <article-title>The humanized anti-HM1.24 antibody effectively kills multiple myeloma cells by human effector cell-mediated cytotoxicity</article-title>. <source>Mol Immunol</source>
<volume>36</volume>: <fpage>387</fpage>&#x02013;<lpage>395</lpage>. <?supplied-pmid 10444002?><pub-id pub-id-type="pmid">10444002</pub-id></mixed-citation></ref><ref id="pone.0123931.ref028"><label>28</label><mixed-citation publication-type="journal"><name><surname>Tai</surname><given-names>YT</given-names></name>, <name><surname>Horton</surname><given-names>HM</given-names></name>, <name><surname>Kong</surname><given-names>SY</given-names></name>, <name><surname>Pong</surname><given-names>E</given-names></name>, <name><surname>Chen</surname><given-names>H</given-names></name>, <name><surname>Cemerski</surname><given-names>S</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function</article-title>. <source>Blood</source>
<volume>119</volume>: <fpage>2074</fpage>&#x02013;<lpage>2082</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1182/blood-2011-06-364521">10.1182/blood-2011-06-364521</ext-link></comment>
<?supplied-pmid 22246035?><pub-id pub-id-type="pmid">22246035</pub-id></mixed-citation></ref><ref id="pone.0123931.ref029"><label>29</label><mixed-citation publication-type="journal"><name><surname>Yi</surname><given-names>EH</given-names></name>, <name><surname>Yoo</surname><given-names>H</given-names></name>, <name><surname>Noh</surname><given-names>KH</given-names></name>, <name><surname>Han</surname><given-names>S</given-names></name>, <name><surname>Lee</surname><given-names>H</given-names></name>, <name><surname>Won</surname><given-names>C</given-names></name>, <etal>et al</etal> (<year>2013</year>) <article-title>BST-2 is a potential activator of invasion and migration in tamoxifen-resistant breast cancer cells</article-title>. <source>Biochem Biophys Res Commun</source>
<volume>435</volume>: <fpage>685</fpage>&#x02013;<lpage>690</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.bbrc.2013.05.043">10.1016/j.bbrc.2013.05.043</ext-link></comment>
<?supplied-pmid 23702480?><pub-id pub-id-type="pmid">23702480</pub-id></mixed-citation></ref><ref id="pone.0123931.ref030"><label>30</label><mixed-citation publication-type="journal"><name><surname>Sayeed</surname><given-names>A</given-names></name>, <name><surname>Luciani-Torres</surname><given-names>G</given-names></name>, <name><surname>Meng</surname><given-names>Z</given-names></name>, <name><surname>Bennington</surname><given-names>JL</given-names></name>, <name><surname>Moore</surname><given-names>DH</given-names></name>, <name><surname>Dairkee</surname><given-names>SH</given-names></name> (<year>2013</year>) <article-title>Aberrant regulation of the BST2 (Tetherin) promoter enhances cell proliferation and apoptosis evasion in high grade breast cancer cells</article-title>. <source>PLoS One</source>
<volume>8</volume>: <fpage>e67191</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0067191">10.1371/journal.pone.0067191</ext-link></comment>
<?supplied-pmid 23840623?><pub-id pub-id-type="pmid">23840623</pub-id></mixed-citation></ref><ref id="pone.0123931.ref031"><label>31</label><mixed-citation publication-type="journal"><name><surname>Jovanovic</surname><given-names>J</given-names></name>, <name><surname>Ronneberg</surname><given-names>JA</given-names></name>, <name><surname>Tost</surname><given-names>J</given-names></name>, <name><surname>Kristensen</surname><given-names>V</given-names></name> (<year>2010</year>) <article-title>The epigenetics of breast cancer</article-title>. <source>Mol Oncol</source>
<volume>4</volume>: <fpage>242</fpage>&#x02013;<lpage>254</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.molonc.2010.04.002">10.1016/j.molonc.2010.04.002</ext-link></comment>
<?supplied-pmid 20627830?><pub-id pub-id-type="pmid">20627830</pub-id></mixed-citation></ref><ref id="pone.0123931.ref032"><label>32</label><mixed-citation publication-type="journal"><name><surname>Razin</surname><given-names>A</given-names></name>, <name><surname>Szyf</surname><given-names>M</given-names></name> (<year>1984</year>) <article-title>DNA methylation patterns. Formation and function</article-title>. <source>Biochim Biophys Acta</source>
<volume>782</volume>: <fpage>331</fpage>&#x02013;<lpage>342</lpage>. <?supplied-pmid 6383476?><pub-id pub-id-type="pmid">6383476</pub-id></mixed-citation></ref><ref id="pone.0123931.ref033"><label>33</label><mixed-citation publication-type="journal"><name><surname>Rauch</surname><given-names>TA</given-names></name>, <name><surname>Wu</surname><given-names>X</given-names></name>, <name><surname>Zhong</surname><given-names>X</given-names></name>, <name><surname>Riggs</surname><given-names>AD</given-names></name>, <name><surname>Pfeifer</surname><given-names>GP</given-names></name> (<year>2009</year>) <article-title>A human B cell methylome at 100-base pair resolution</article-title>. <source>Proc Natl Acad Sci U S A</source>
<volume>106</volume>: <fpage>671</fpage>&#x02013;<lpage>678</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1073/pnas.0812399106">10.1073/pnas.0812399106</ext-link></comment>
<?supplied-pmid 19139413?><pub-id pub-id-type="pmid">19139413</pub-id></mixed-citation></ref><ref id="pone.0123931.ref034"><label>34</label><mixed-citation publication-type="journal"><name><surname>Razin</surname><given-names>A</given-names></name>, <name><surname>Cedar</surname><given-names>H</given-names></name> (<year>1977</year>) <article-title>Distribution of 5-methylcytosine in chromatin</article-title>. <source>Proc Natl Acad Sci U S A</source>
<volume>74</volume>: <fpage>2725</fpage>&#x02013;<lpage>2728</lpage>. <?supplied-pmid 268622?><pub-id pub-id-type="pmid">268622</pub-id></mixed-citation></ref><ref id="pone.0123931.ref035"><label>35</label><mixed-citation publication-type="journal"><name><surname>Ting</surname><given-names>AH</given-names></name>, <name><surname>McGarvey</surname><given-names>KM</given-names></name>, <name><surname>Baylin</surname><given-names>SB</given-names></name> (<year>2006</year>) <article-title>The cancer epigenome&#x02014;components and functional correlates</article-title>. <source>Genes Dev</source>
<volume>20</volume>: <fpage>3215</fpage>&#x02013;<lpage>3231</lpage>. <?supplied-pmid 17158741?><pub-id pub-id-type="pmid">17158741</pub-id></mixed-citation></ref><ref id="pone.0123931.ref036"><label>36</label><mixed-citation publication-type="journal"><name><surname>Schweiger</surname><given-names>MR</given-names></name>, <name><surname>Barmeyer</surname><given-names>C</given-names></name>, <name><surname>Timmermann</surname><given-names>B</given-names></name> (<year>2013</year>) <article-title>Genomics and epigenomics: new promises of personalized medicine for cancer patients</article-title>. <source>Brief Funct Genomics</source>
<volume>12</volume>: <fpage>411</fpage>&#x02013;<lpage>421</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/bfgp/elt024">10.1093/bfgp/elt024</ext-link></comment>
<?supplied-pmid 23814132?><pub-id pub-id-type="pmid">23814132</pub-id></mixed-citation></ref><ref id="pone.0123931.ref037"><label>37</label><mixed-citation publication-type="journal"><name><surname>Zhu</surname><given-names>J</given-names></name>, <name><surname>Sanborn</surname><given-names>JZ</given-names></name>, <name><surname>Benz</surname><given-names>S</given-names></name>, <name><surname>Szeto</surname><given-names>C</given-names></name>, <name><surname>Hsu</surname><given-names>F</given-names></name>, <name><surname>Kuhn</surname><given-names>RM</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>The UCSC Cancer Genomics Browser</article-title>. <source>Nat Methods</source>
<volume>6</volume>: <fpage>239</fpage>&#x02013;<lpage>240</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nmeth0409-239">10.1038/nmeth0409-239</ext-link></comment>
<?supplied-pmid 19333237?><pub-id pub-id-type="pmid">19333237</pub-id></mixed-citation></ref><ref id="pone.0123931.ref038"><label>38</label><mixed-citation publication-type="journal"><name><surname>Cline</surname><given-names>MS</given-names></name>, <name><surname>Craft</surname><given-names>B</given-names></name>, <name><surname>Swatloski</surname><given-names>T</given-names></name>, <name><surname>Goldman</surname><given-names>M</given-names></name>, <name><surname>Ma</surname><given-names>S</given-names></name>, <name><surname>Haussler</surname><given-names>D</given-names></name>, <etal>et al</etal> (<year>2013</year>) <article-title>Exploring TCGA Pan-Cancer data at the UCSC Cancer Genomics Browser</article-title>. <source>Sci Rep</source>
<volume>3</volume>: <fpage>2652</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/srep02652">10.1038/srep02652</ext-link></comment>
<?supplied-pmid 24084870?><pub-id pub-id-type="pmid">24084870</pub-id></mixed-citation></ref><ref id="pone.0123931.ref039"><label>39</label><mixed-citation publication-type="journal"><name><surname>Weinstein</surname><given-names>JN</given-names></name>, <name><surname>Collisson</surname><given-names>EA</given-names></name>, <name><surname>Mills</surname><given-names>GB</given-names></name>, <name><surname>Shaw</surname><given-names>KR</given-names></name>, <name><surname>Ozenberger</surname><given-names>BA</given-names></name>, <name><surname>Ellrott</surname><given-names>K</given-names></name>, <etal>et al</etal> (<year>2013</year>) <article-title>The Cancer Genome Atlas Pan-Cancer analysis project</article-title>. <source>Nat Genet</source>
<volume>45</volume>: <fpage>1113</fpage>&#x02013;<lpage>1120</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/ng.2764">10.1038/ng.2764</ext-link></comment>
<?supplied-pmid 24071849?><pub-id pub-id-type="pmid">24071849</pub-id></mixed-citation></ref><ref id="pone.0123931.ref040"><label>40</label><mixed-citation publication-type="journal"><name><surname>Casey</surname><given-names>T</given-names></name>, <name><surname>Bond</surname><given-names>J</given-names></name>, <name><surname>Tighe</surname><given-names>S</given-names></name>, <name><surname>Hunter</surname><given-names>T</given-names></name>, <name><surname>Lintault</surname><given-names>L</given-names></name>, <name><surname>Patel</surname><given-names>O</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Molecular signatures suggest a major role for stromal cells in development of invasive breast cancer</article-title>. <source>Breast Cancer Res Treat</source>
<volume>114</volume>: <fpage>47</fpage>&#x02013;<lpage>62</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s10549-008-9982-8">10.1007/s10549-008-9982-8</ext-link></comment>
<?supplied-pmid 18373191?><pub-id pub-id-type="pmid">18373191</pub-id></mixed-citation></ref><ref id="pone.0123931.ref041"><label>41</label><mixed-citation publication-type="journal"><name><surname>Riaz</surname><given-names>M</given-names></name>, <name><surname>van Jaarsveld</surname><given-names>MT</given-names></name>, <name><surname>Hollestelle</surname><given-names>A</given-names></name>, <name><surname>Prager-van der Smissen</surname><given-names>WJ</given-names></name>, <name><surname>Heine</surname><given-names>AA</given-names></name>, <name><surname>Boersma</surname><given-names>AW</given-names></name>, <etal>et al</etal> (<year>2013</year>) <article-title>miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs</article-title>. <source>Breast Cancer Res</source>
<volume>15</volume>: <fpage>R33</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/bcr3415">10.1186/bcr3415</ext-link></comment>
<?supplied-pmid 23601657?><pub-id pub-id-type="pmid">23601657</pub-id></mixed-citation></ref><ref id="pone.0123931.ref042"><label>42</label><mixed-citation publication-type="journal"><name><surname>Yamamoto</surname><given-names>S</given-names></name>, <name><surname>Wu</surname><given-names>Z</given-names></name>, <name><surname>Russnes</surname><given-names>HG</given-names></name>, <name><surname>Takagi</surname><given-names>S</given-names></name>, <name><surname>Peluffo</surname><given-names>G</given-names></name>, <name><surname>Vaske</surname><given-names>C</given-names></name>, <etal>et al</etal> (<year>2014</year>) <article-title>JARID1B is a luminal lineage-driving oncogene in breast cancer</article-title>. <source>Cancer Cell</source>
<volume>25</volume>: <fpage>762</fpage>&#x02013;<lpage>777</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.ccr.2014.04.024">10.1016/j.ccr.2014.04.024</ext-link></comment>
<?supplied-pmid 24937458?><pub-id pub-id-type="pmid">24937458</pub-id></mixed-citation></ref><ref id="pone.0123931.ref043"><label>43</label><mixed-citation publication-type="journal"><name><surname>Radpour</surname><given-names>R</given-names></name>, <name><surname>Barekati</surname><given-names>Z</given-names></name>, <name><surname>Kohler</surname><given-names>C</given-names></name>, <name><surname>Schumacher</surname><given-names>MM</given-names></name>, <name><surname>Grussenmeyer</surname><given-names>T</given-names></name>, <name><surname>Jenoe</surname><given-names>P</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Integrated epigenetics of human breast cancer: synoptic investigation of targeted genes, microRNAs and proteins upon demethylation treatment</article-title>. <source>PLoS One</source>
<volume>6</volume>: <fpage>e27355</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0027355">10.1371/journal.pone.0027355</ext-link></comment>
<?supplied-pmid 22076154?><pub-id pub-id-type="pmid">22076154</pub-id></mixed-citation></ref><ref id="pone.0123931.ref044"><label>44</label><mixed-citation publication-type="journal"><name><surname>Putnik</surname><given-names>M</given-names></name>, <name><surname>Zhao</surname><given-names>C</given-names></name>, <name><surname>Gustafsson</surname><given-names>JA</given-names></name>, <name><surname>Dahlman-Wright</surname><given-names>K</given-names></name> (<year>2012</year>) <article-title>Global identification of genes regulated by estrogen signaling and demethylation in MCF-7 breast cancer cells</article-title>. <source>Biochem Biophys Res Commun</source>
<volume>426</volume>: <fpage>26</fpage>&#x02013;<lpage>32</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.bbrc.2012.08.007">10.1016/j.bbrc.2012.08.007</ext-link></comment>
<?supplied-pmid 22902638?><pub-id pub-id-type="pmid">22902638</pub-id></mixed-citation></ref><ref id="pone.0123931.ref045"><label>45</label><mixed-citation publication-type="journal"><name><surname>Jones</surname><given-names>PH</given-names></name>, <name><surname>Mahauad-Fernandez</surname><given-names>WD</given-names></name>, <name><surname>Madison</surname><given-names>MN</given-names></name>, <name><surname>Okeoma</surname><given-names>CM</given-names></name> (<year>2013</year>) <article-title>BST-2/tetherin is overexpressed in mammary gland and tumor tissues in MMTV-induced mammary cancer</article-title>. <source>Virology</source>
<volume>444</volume>: <fpage>124</fpage>&#x02013;<lpage>139</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.virol.2013.05.042">10.1016/j.virol.2013.05.042</ext-link></comment>
<?supplied-pmid 23806386?><pub-id pub-id-type="pmid">23806386</pub-id></mixed-citation></ref><ref id="pone.0123931.ref046"><label>46</label><mixed-citation publication-type="journal"><name><surname>Jones</surname><given-names>PH</given-names></name>, <name><surname>Mehta</surname><given-names>HV</given-names></name>, <name><surname>Okeoma</surname><given-names>CM</given-names></name> (<year>2012</year>) <article-title>A novel role for APOBEC3: susceptibility to sexual transmission of murine acquired immunodeficiency virus (mAIDS) is aggravated in APOBEC3 deficient mice</article-title>. <source>Retrovirology</source>
<volume>9</volume>: <fpage>50</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/1742-4690-9-50">10.1186/1742-4690-9-50</ext-link></comment>
<?supplied-pmid 22691411?><pub-id pub-id-type="pmid">22691411</pub-id></mixed-citation></ref><ref id="pone.0123931.ref047"><label>47</label><mixed-citation publication-type="journal"><name><surname>Mehta</surname><given-names>HV</given-names></name>, <name><surname>Jones</surname><given-names>PH</given-names></name>, <name><surname>Weiss</surname><given-names>JP</given-names></name>, <name><surname>Okeoma</surname><given-names>CM</given-names></name> (<year>2012</year>) <article-title>IFN-alpha and lipopolysaccharide upregulate APOBEC3 mRNA through different signaling pathways</article-title>. <source>J Immunol</source>
<volume>189</volume>: <fpage>4088</fpage>&#x02013;<lpage>4103</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.4049/jimmunol.1200777">10.4049/jimmunol.1200777</ext-link></comment>
<?supplied-pmid 22972924?><pub-id pub-id-type="pmid">22972924</pub-id></mixed-citation></ref><ref id="pone.0123931.ref048"><label>48</label><mixed-citation publication-type="journal"><name><surname>Madison</surname><given-names>MN</given-names></name>, <name><surname>Roller</surname><given-names>RJ</given-names></name>, <name><surname>Okeoma</surname><given-names>CM</given-names></name> (<year>2014</year>) <article-title>Human semen contains exosomes with potent anti-HIV-1 activity</article-title>. <source>Retrovirology</source>
<volume>11</volume>: <fpage>102</fpage>
<?supplied-pmid 25407601?><pub-id pub-id-type="pmid">25407601</pub-id></mixed-citation></ref><ref id="pone.0123931.ref049"><label>49</label><mixed-citation publication-type="journal"><name><surname>Mehta</surname><given-names>HV</given-names></name>, <name><surname>Jones</surname><given-names>PH</given-names></name>, <name><surname>Weiss</surname><given-names>JP</given-names></name>, <name><surname>Okeoma</surname><given-names>CM</given-names></name> (<year>2012</year>) <article-title>IFN-alpha and Lipopolysaccharide Upregulate APOBEC3 mRNA through Different Signaling Pathways</article-title>. <source>J Immunol</source>.</mixed-citation></ref><ref id="pone.0123931.ref050"><label>50</label><mixed-citation publication-type="journal"><name><surname>Jones</surname><given-names>PH</given-names></name>, <name><surname>Okeoma</surname><given-names>CM</given-names></name> (<year>2013</year>) <article-title>Phosphatidylinositol 3- kinase is involved in Toll-like receptor 4-mediated BST-2/Tetherin regulation</article-title>. <source>Cell Signal</source>.</mixed-citation></ref><ref id="pone.0123931.ref051"><label>51</label><mixed-citation publication-type="journal"><name><surname>Tao</surname><given-names>Y</given-names></name>, <name><surname>Liu</surname><given-names>S</given-names></name>, <name><surname>Briones</surname><given-names>V</given-names></name>, <name><surname>Geiman</surname><given-names>TM</given-names></name>, <name><surname>Muegge</surname><given-names>K</given-names></name> (<year>2011</year>) <article-title>Treatment of breast cancer cells with DNA demethylating agents leads to a release of Pol II stalling at genes with DNA-hypermethylated regions upstream of TSS</article-title>. <source>Nucleic Acids Res</source>
<volume>39</volume>: <fpage>9508</fpage>&#x02013;<lpage>9520</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/nar/gkr611">10.1093/nar/gkr611</ext-link></comment>
<?supplied-pmid 21880597?><pub-id pub-id-type="pmid">21880597</pub-id></mixed-citation></ref><ref id="pone.0123931.ref052"><label>52</label><mixed-citation publication-type="journal"><name><surname>Gius</surname><given-names>D</given-names></name>, <name><surname>Cui</surname><given-names>H</given-names></name>, <name><surname>Bradbury</surname><given-names>CM</given-names></name>, <name><surname>Cook</surname><given-names>J</given-names></name>, <name><surname>Smart</surname><given-names>DK</given-names></name>, <name><surname>Zhao</surname><given-names>S</given-names></name>, <etal>et al</etal> (<year>2004</year>) <article-title>Distinct effects on gene expression of chemical and genetic manipulation of the cancer epigenome revealed by a multimodality approach</article-title>. <source>Cancer Cell</source>
<volume>6</volume>: <fpage>361</fpage>&#x02013;<lpage>371</lpage>. <?supplied-pmid 15488759?><pub-id pub-id-type="pmid">15488759</pub-id></mixed-citation></ref><ref id="pone.0123931.ref053"><label>53</label><mixed-citation publication-type="journal"><name><surname>Schuebel</surname><given-names>KE</given-names></name>, <name><surname>Chen</surname><given-names>W</given-names></name>, <name><surname>Cope</surname><given-names>L</given-names></name>, <name><surname>Glockner</surname><given-names>SC</given-names></name>, <name><surname>Suzuki</surname><given-names>H</given-names></name>, <name><surname>Yi</surname><given-names>M</given-names></name>, <etal>et al</etal> (<year>2007</year>) <article-title>Comparing the DNA hypermethylome with gene mutations in human colorectal cancer</article-title>. <source>PLoS Genet</source>
<volume>3</volume>: <fpage>1709</fpage>&#x02013;<lpage>1723</lpage>. <?supplied-pmid 17892325?><pub-id pub-id-type="pmid">17892325</pub-id></mixed-citation></ref><ref id="pone.0123931.ref054"><label>54</label><mixed-citation publication-type="journal"><name><surname>Gama-Sosa</surname><given-names>MA</given-names></name>, <name><surname>Slagel</surname><given-names>VA</given-names></name>, <name><surname>Trewyn</surname><given-names>RW</given-names></name>, <name><surname>Oxenhandler</surname><given-names>R</given-names></name>, <name><surname>Kuo</surname><given-names>KC</given-names></name>, <name><surname>Gehrke</surname><given-names>CW</given-names></name>, <etal>et al</etal> (<year>1983</year>) <article-title>The 5-methylcytosine content of DNA from human tumors</article-title>. <source>Nucleic Acids Res</source>
<volume>11</volume>: <fpage>6883</fpage>&#x02013;<lpage>6894</lpage>. <?supplied-pmid 6314264?><pub-id pub-id-type="pmid">6314264</pub-id></mixed-citation></ref><ref id="pone.0123931.ref055"><label>55</label><mixed-citation publication-type="journal"><name><surname>de Capoa</surname><given-names>A</given-names></name>, <name><surname>Musolino</surname><given-names>A</given-names></name>, <name><surname>Della Rosa</surname><given-names>S</given-names></name>, <name><surname>Caiafa</surname><given-names>P</given-names></name>, <name><surname>Mariani</surname><given-names>L</given-names></name>, <name><surname>Del Nonno</surname><given-names>F</given-names></name>, <etal>et al</etal> (<year>2003</year>) <article-title>DNA demethylation is directly related to tumour progression: evidence in normal, pre-malignant and malignant cells from uterine cervix samples</article-title>. <source>Oncol Rep</source>
<volume>10</volume>: <fpage>545</fpage>&#x02013;<lpage>549</lpage>. <?supplied-pmid 12684621?><pub-id pub-id-type="pmid">12684621</pub-id></mixed-citation></ref><ref id="pone.0123931.ref056"><label>56</label><mixed-citation publication-type="journal"><name><surname>Bedford</surname><given-names>MT</given-names></name>, <name><surname>van Helden</surname><given-names>PD</given-names></name> (<year>1987</year>) <article-title>Hypomethylation of DNA in pathological conditions of the human prostate</article-title>. <source>Cancer Res</source>
<volume>47</volume>: <fpage>5274</fpage>&#x02013;<lpage>5276</lpage>. <?supplied-pmid 2443238?><pub-id pub-id-type="pmid">2443238</pub-id></mixed-citation></ref><ref id="pone.0123931.ref057"><label>57</label><mixed-citation publication-type="journal"><name><surname>Herman</surname><given-names>JG</given-names></name>, <name><surname>Baylin</surname><given-names>SB</given-names></name> (<year>2003</year>) <article-title>Gene silencing in cancer in association with promoter hypermethylation</article-title>. <source>N Engl J Med</source>
<volume>349</volume>: <fpage>2042</fpage>&#x02013;<lpage>2054</lpage>. <?supplied-pmid 14627790?><pub-id pub-id-type="pmid">14627790</pub-id></mixed-citation></ref><ref id="pone.0123931.ref058"><label>58</label><mixed-citation publication-type="journal"><name><surname>Ferguson</surname><given-names>AT</given-names></name>, <name><surname>Vertino</surname><given-names>PM</given-names></name>, <name><surname>Spitzner</surname><given-names>JR</given-names></name>, <name><surname>Baylin</surname><given-names>SB</given-names></name>, <name><surname>Muller</surname><given-names>MT</given-names></name>, <name><surname>Davidson</surname><given-names>NE</given-names></name> (<year>1997</year>) <article-title>Role of estrogen receptor gene demethylation and DNA methyltransferase. DNA adduct formation in 5-aza-2'deoxycytidine-induced cytotoxicity in human breast cancer cells</article-title>. <source>J Biol Chem</source>
<volume>272</volume>: <fpage>32260</fpage>&#x02013;<lpage>32266</lpage>. <?supplied-pmid 9405430?><pub-id pub-id-type="pmid">9405430</pub-id></mixed-citation></ref><ref id="pone.0123931.ref059"><label>59</label><mixed-citation publication-type="journal"><name><surname>Ehrlich</surname><given-names>M</given-names></name> (<year>2002</year>) <article-title>DNA hypomethylation, cancer, the immunodeficiency, centromeric region instability, facial anomalies syndrome and chromosomal rearrangements</article-title>. <source>J Nutr</source>
<volume>132</volume>: <fpage>2424s</fpage>&#x02013;<lpage>2429s</lpage>. <?supplied-pmid 12163705?><pub-id pub-id-type="pmid">12163705</pub-id></mixed-citation></ref><ref id="pone.0123931.ref060"><label>60</label><mixed-citation publication-type="journal"><name><surname>Ehrlich</surname><given-names>M</given-names></name>, <name><surname>Woods</surname><given-names>CB</given-names></name>, <name><surname>Yu</surname><given-names>MC</given-names></name>, <name><surname>Dubeau</surname><given-names>L</given-names></name>, <name><surname>Yang</surname><given-names>F</given-names></name>, <name><surname>Campan</surname><given-names>M</given-names></name>, <etal>et al</etal> (<year>2006</year>) <article-title>Quantitative analysis of associations between DNA hypermethylation, hypomethylation, and DNMT RNA levels in ovarian tumors</article-title>. <source>Oncogene</source>
<volume>25</volume>: <fpage>2636</fpage>&#x02013;<lpage>2645</lpage>. <?supplied-pmid 16532039?><pub-id pub-id-type="pmid">16532039</pub-id></mixed-citation></ref><ref id="pone.0123931.ref061"><label>61</label><mixed-citation publication-type="journal"><name><surname>Son</surname><given-names>KS</given-names></name>, <name><surname>Kang</surname><given-names>HS</given-names></name>, <name><surname>Kim</surname><given-names>SJ</given-names></name>, <name><surname>Jung</surname><given-names>SY</given-names></name>, <name><surname>Min</surname><given-names>SY</given-names></name>, <name><surname>Lee</surname><given-names>SY</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Hypomethylation of the interleukin-10 gene in breast cancer tissues</article-title>. <source>Breast</source>
<volume>19</volume>: <fpage>484</fpage>&#x02013;<lpage>488</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.breast.2010.05.011">10.1016/j.breast.2010.05.011</ext-link></comment>
<?supplied-pmid 20646924?><pub-id pub-id-type="pmid">20646924</pub-id></mixed-citation></ref><ref id="pone.0123931.ref062"><label>62</label><mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>Z</given-names></name>, <name><surname>Zhang</surname><given-names>J</given-names></name>, <name><surname>Zhang</surname><given-names>Y</given-names></name>, <name><surname>Lim</surname><given-names>SH</given-names></name> (<year>2006</year>) <article-title>SPAN-Xb expression in myeloma cells is dependent on promoter hypomethylation and can be upregulated pharmacologically</article-title>. <source>Int J Cancer</source>
<volume>118</volume>: <fpage>1436</fpage>&#x02013;<lpage>1444</lpage>. <?supplied-pmid 16187275?><pub-id pub-id-type="pmid">16187275</pub-id></mixed-citation></ref><ref id="pone.0123931.ref063"><label>63</label><mixed-citation publication-type="journal"><collab>Cancer Genome Atlas Network</collab> (<year>2012</year>) <article-title>Comprehensive molecular portraits of human breast tumours</article-title>. <source>Nature</source>
<volume>490</volume>: <fpage>61</fpage>&#x02013;<lpage>70</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nature11412">10.1038/nature11412</ext-link></comment>
<?supplied-pmid 23000897?><pub-id pub-id-type="pmid">23000897</pub-id></mixed-citation></ref><ref id="pone.0123931.ref064"><label>64</label><mixed-citation publication-type="journal"><name><surname>Kawai</surname><given-names>S</given-names></name>, <name><surname>Azuma</surname><given-names>Y</given-names></name>, <name><surname>Fujii</surname><given-names>E</given-names></name>, <name><surname>Furugaki</surname><given-names>K</given-names></name>, <name><surname>Ozaki</surname><given-names>S</given-names></name>, <name><surname>Matsumoto</surname><given-names>T</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>Interferon-alpha enhances CD317 expression and the antitumor activity of anti-CD317 monoclonal antibody in renal cell carcinoma xenograft models</article-title>. <source>Cancer Sci</source>
<volume>99</volume>: <fpage>2461</fpage>&#x02013;<lpage>2466</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1349-7006.2008.00968.x">10.1111/j.1349-7006.2008.00968.x</ext-link></comment>
<?supplied-pmid 19032371?><pub-id pub-id-type="pmid">19032371</pub-id></mixed-citation></ref><ref id="pone.0123931.ref065"><label>65</label><mixed-citation publication-type="journal"><name><surname>Bego</surname><given-names>MG</given-names></name>, <name><surname>Mercier</surname><given-names>J</given-names></name>, <name><surname>Cohen</surname><given-names>EA</given-names></name> (<year>2012</year>) <article-title>Virus-activated interferon regulatory factor 7 upregulates expression of the interferon-regulated BST2 gene independently of interferon signaling</article-title>. <source>J Virol</source>
<volume>86</volume>: <fpage>3513</fpage>&#x02013;<lpage>3527</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/JVI.06971-11">10.1128/JVI.06971-11</ext-link></comment>
<?supplied-pmid 22301143?><pub-id pub-id-type="pmid">22301143</pub-id></mixed-citation></ref><ref id="pone.0123931.ref066"><label>66</label><mixed-citation publication-type="journal"><name><surname>Varley</surname><given-names>KE</given-names></name>, <name><surname>Gertz</surname><given-names>J</given-names></name>, <name><surname>Bowling</surname><given-names>KM</given-names></name>, <name><surname>Parker</surname><given-names>SL</given-names></name>, <name><surname>Reddy</surname><given-names>TE</given-names></name>, <name><surname>Pauli-Behn</surname><given-names>F</given-names></name>, <etal>et al</etal> (<year>2013</year>) <article-title>Dynamic DNA methylation across diverse human cell lines and tissues</article-title>. <source>Genome Res</source>
<volume>23</volume>: <fpage>555</fpage>&#x02013;<lpage>567</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1101/gr.147942.112">10.1101/gr.147942.112</ext-link></comment>
<?supplied-pmid 23325432?><pub-id pub-id-type="pmid">23325432</pub-id></mixed-citation></ref><ref id="pone.0123931.ref067"><label>67</label><mixed-citation publication-type="journal"><name><surname>Cui</surname><given-names>W</given-names></name>, <name><surname>Wang</surname><given-names>LH</given-names></name>, <name><surname>Wen</surname><given-names>YY</given-names></name>, <name><surname>Song</surname><given-names>M</given-names></name>, <name><surname>Li</surname><given-names>BL</given-names></name>, <name><surname>Chen</surname><given-names>XL</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Expression and regulation mechanisms of Sonic Hedgehog in breast cancer</article-title>. <source>Cancer Sci</source>
<volume>101</volume>: <fpage>927</fpage>&#x02013;<lpage>933</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1349-7006.2010.01495.x">10.1111/j.1349-7006.2010.01495.x</ext-link></comment>
<?supplied-pmid 20180807?><pub-id pub-id-type="pmid">20180807</pub-id></mixed-citation></ref><ref id="pone.0123931.ref068"><label>68</label><mixed-citation publication-type="journal"><name><surname>Milicic</surname><given-names>A</given-names></name>, <name><surname>Harrison</surname><given-names>LA</given-names></name>, <name><surname>Goodlad</surname><given-names>RA</given-names></name>, <name><surname>Hardy</surname><given-names>RG</given-names></name>, <name><surname>Nicholson</surname><given-names>AM</given-names></name>, <name><surname>Presz</surname><given-names>M</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>Ectopic expression of P-cadherin correlates with promoter hypomethylation early in colorectal carcinogenesis and enhanced intestinal crypt fission in vivo</article-title>. <source>Cancer Res</source>
<volume>68</volume>: <fpage>7760</fpage>&#x02013;<lpage>7768</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1158/0008-5472.CAN-08-0020">10.1158/0008-5472.CAN-08-0020</ext-link></comment>
<?supplied-pmid 18829530?><pub-id pub-id-type="pmid">18829530</pub-id></mixed-citation></ref><ref id="pone.0123931.ref069"><label>69</label><mixed-citation publication-type="journal"><name><surname>Hibi</surname><given-names>K</given-names></name>, <name><surname>Goto</surname><given-names>T</given-names></name>, <name><surname>Mizukami</surname><given-names>H</given-names></name>, <name><surname>Kitamura</surname><given-names>YH</given-names></name>, <name><surname>Sakuraba</surname><given-names>K</given-names></name>, <name><surname>Sakata</surname><given-names>M</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Demethylation of the CDH3 gene is frequently detected in advanced colorectal cancer</article-title>. <source>Anticancer Res</source>
<volume>29</volume>: <fpage>2215</fpage>&#x02013;<lpage>2217</lpage>. <?supplied-pmid 19528483?><pub-id pub-id-type="pmid">19528483</pub-id></mixed-citation></ref><ref id="pone.0123931.ref070"><label>70</label><mixed-citation publication-type="journal"><name><surname>Etcheverry</surname><given-names>A</given-names></name>, <name><surname>Aubry</surname><given-names>M</given-names></name>, <name><surname>de Tayrac</surname><given-names>M</given-names></name>, <name><surname>Vauleon</surname><given-names>E</given-names></name>, <name><surname>Boniface</surname><given-names>R</given-names></name>, <name><surname>Guenot</surname><given-names>F</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>DNA methylation in glioblastoma: impact on gene expression and clinical outcome</article-title>. <source>BMC Genomics</source>
<volume>11</volume>: <fpage>701</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/1471-2164-11-701">10.1186/1471-2164-11-701</ext-link></comment>
<?supplied-pmid 21156036?><pub-id pub-id-type="pmid">21156036</pub-id></mixed-citation></ref><ref id="pone.0123931.ref071"><label>71</label><mixed-citation publication-type="journal"><name><surname>Coit</surname><given-names>P</given-names></name>, <name><surname>Jeffries</surname><given-names>M</given-names></name>, <name><surname>Altorok</surname><given-names>N</given-names></name>, <name><surname>Dozmorov</surname><given-names>MG</given-names></name>, <name><surname>Koelsch</surname><given-names>KA</given-names></name>, <name><surname>Wren</surname><given-names>JD</given-names></name>, <etal>et al</etal> (<year>2013</year>) <article-title>Genome-wide DNA methylation study suggests epigenetic accessibility and transcriptional poising of interferon-regulated genes in naive CD4+ T cells from lupus patients</article-title>. <source>J Autoimmun</source>
<volume>43</volume>: <fpage>78</fpage>&#x02013;<lpage>84</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.jaut.2013.04.003">10.1016/j.jaut.2013.04.003</ext-link></comment>
<?supplied-pmid 23623029?><pub-id pub-id-type="pmid">23623029</pub-id></mixed-citation></ref></ref-list></back></article>